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 As the world’s elderly population grows, and the incidence of age-related 
diseases increases, knowledge of the factors that affect longevity will be essential to 
develop therapies that counter the effects of aging.  Aging is a highly complex 
phenomenon, but many genetic and environmental lifespan determinants have been 
characterized with the use of model organisms.  Importantly, many of these longevity 
determinants function in human lifespan modulation.  In the nematode C. elegans, the 
transcriptional regulator HCF-1 represses the insulin-responsive transcription factor 
DAF-16 to affect aging and stress responses.  Whether mammalian HCF-1 homologs 
function in a conserved manner to regulate the mammalian DAF-16 homologs, known 
as FoxO transcription factors, has not yet been determined. 
 My studies indicate that HCF-1 proteins interact with FoxO transcription 
factors, and regulate the transcriptional targets of FoxO in mammalian cells.  
Furthermore, while the DAF-16 co-regulator SIR-2.1 acts upstream of C. elegans 
HCF-1 to modulate lifespan, the mammalian homolog of SIR-2.1, SIRT1, targets 
mammalian HCF-1 for deacetylation.  These findings highlight the well-conserved 
nature of the interaction between FoxO transcription factors and the FoxO co-
 regulators HCF-1 and SIRT1, and implicate HCF-1 as a novel longevity determinant 
in mammals. 
 FoxO transcription factors are critical regulators of multiple physiological 
processes, including the maintenance of glucose homeostasis.  In the pancreas, FoxO1 
regulates β-cell function through repression of the transcription factor Pdx1.  My 
analyses indicate that HCF-1 is required for survival, proliferation and glucose-
stimulated insulin secretion in the INS-1 β-cell line.  Inactivation of HCF-1 leads to 
reduced Pdx1 gene transcription and resultant decreases in insulin gene transcription 
and cellular insulin content.  However, while HCF-1 and FoxO1 physically interact in 
β-cells, FoxO1 localization to the Pdx1 promoter is not increased by HCF-1 depletion, 
suggesting that HCF-1 promotes transcription of Pdx1 through a FoxO1-independent 
mechanism.  Rather, I find that HCF-1 associates with the transcription factor E2F1, 
which is also known to affect Pdx1 expression.  Both HCF-1 and E2F1 localize to the 
promoter of the Pdx1 gene, suggesting that HCF-1, in association with E2F1, directly 
promotes Pdx1 gene expression.  Thus, my results implicate HCF-1 as a critical 
modulator of both mammalian glucose homoestasis and longevity.   
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  CHAPTER 1 
 
INTRODUCTION 
The Centers for Disease Control and Prevention estimates that by 2030, the 
number of U.S. adults aged 65 or older will more than double to over 70 million 
individuals.  Aging is a major risk factor for the development of many diseases, 
including osteoporosis, cancer, cardiovascular disease, and neurodegenerative 
disorders.  Thus, identifying and characterizing the factors leading to functional 
decline with age is a major priority in developing therapies that can prevent or delay 
the onset of disease.  Aging is recognized to be a highly complex process, involving 
interactions between an organism’s genetic background and environment.  Therefore, 
to facilitate the identification of factors involved in the determination of lifespan and 
healthspan, many of the studies aimed at elucidating the biology of aging have utilized 
the genetic model organism Caenorhabditis elegans.   As a result of these efforts, 
numerous genetic factors that influence the aging process have been discovered, and 
importantly, many of these genes have subsequently been demonstrated to affect aging 
in mammals.  The example of the insulin/IGF-1 signaling (IIS) pathway serves to 
highlight the enormous contribution made by research first initiated by investigating 
aging in C. elegans.  
In C. elegans, mutations that disrupt the IIS pathway extend lifespan up to 
twice that of wildtype animals (Kenyon et al., 1993).  As a consequence of reduced 
insulin signaling, the forkhead box, class O (FoxO) transcription factor DAF-16 is 
activated, thereby allowing for the expression of a multitude of lifespan extending 
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genes.  Subsequent studies revealed that IIS plays a similar role in determining the 
lifespan of both flies and mice (Tatar et al., 2001; Bluher et al., 2003; Holzenberger et 
al., 2003).  These findings lent support to the idea that, due to the evolutionarily 
conserved nature of longevity-affecting genes, studies in relatively simple organisms 
like C. elegans could provide valuable insight into the aging process of humans.  As 
further evidence in support of this premise, recent studies have shown significant 
association between longevity and polymorphisms within genes encoding the human 
insulin receptor (Kojima et al., 2004), the IGF-1 receptor (Suh et al., 2008), the protein 
kinase AKT (Pawlikowska et al., 2009), and both FoxO1 and FoxO3 (Willcox et al., 
2008; Anselmi et al., 2009; Flachsbart et al., 2009; Li et al., 2009; Pawlikowska et al., 
2009).    
The field of aging has experienced incredible growth with the identification of 
many novel factors involved in C. elegans lifespan determination.   The transcriptional 
co-regulator Host Cell Factor 1 (HCF-1) was identified as a longevity determinant, 
and novel co-repressor of DAF-16, the major longevity-promoting factor downstream 
of the IIS pathway (Li et al., 2008a).  HCF-1, like DAF-16/FoxO, is evolutionarily 
conserved between worms and humans, suggesting that HCF-1 represents a novel 
human longevity factor as well.  Better understanding the function and regulation of 
HCF-1 in mammals will thus provide a valuable first step in elucidating the specific 
roles putative longevity factors play in complex organisms, and will shed light on the 
complex interactions between various factors that control the aging process.       
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1.1 Host Cell Factor 1 
Since the discovery of FoxO transcription factors as key longevity modulators, 
a multitude of studies have sought to describe in fine detail the regulation of these 
transcription factors.    Investigations over the past decade have revealed an elegant 
network of interactions governing the activity of FoxO proteins.  The relationship 
between multiple extracellular signals, intracellular components and nuclear factors 
provide inputs that modulate FoxO transcriptional activity in a highly specific manner 
(Calnan and Brunet, 2008; Landis and Murphy, 2010; Daitoku et al., 2011).   Of the 
nuclear co-factors of DAF-16 in C. elegans, HCF-1 represents the first nuclear co-
repressor of DAF-16 to be identified. 
  C. elegans HCF-1 was first identified in a genome-wide RNAi screen as a 
novel longevity determinant (Hamilton et al., 2005).  Knockdown or mutation of hcf-1 
leads to robust and significant lifespan extension as well as increased oxidative and 
heavy-metal stress resistance, these phenotypes being dependent on daf-16 (Li et al., 
2008a).  HCF-1 associates with DAF-16 in the nucleus and in doing so, prevents 
DAF-16 localization to a subset of its target genes’ promoters (Li et al., 2008a).  
Further investigation revealed that C. elegans hcf-1 acts downstream of the C. elegans 
sirtuin sir-2.1 to affect both stress resistance and lifespan (Rizki et al., 2011).  HCF-1 
and SIR-2.1 physically associate and share in the regulation of a large number of 
DAF-16 target genes important for aging and stress response (Rizki et al., 2011). 
Notably, HCF-1, like FoxO and insulin/IGF1 signaling, is highly conserved 
across species.  In mammals, two homologs of C. elegans HCF-1 are present, HCF-1 
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and HCF-2.     While mammalian HCF-1’s role as a transcriptional regulator has been 
characterized, no clear function of mammalian HCF-2 has been determined.   
Human HCF-1 was first identified as a cellular protein which interacts with 
Oct-1 and the herpes simplex virus protein VP16 to form a transcriptional complex 
responsible for viral immediate early gene activation (Gerster and Roeder, 1988; 
Kristie and Sharp, 1993).  Subsequent studies showed that HCF-1 is required for 
multiple aspects of cell cycle progression (Goto et al., 1997; Wilson et al., 1997; 
Julien and Herr, 2003, 2004),  DNA damage induced apoptosis (Tyagi and Herr, 2009) 
and embryonic stem cell (ESC) pluripotency (Dejosez et al., 2008; Dejosez et al., 
2010).  HCF-1 functions as a transcriptional regulator for a diverse array of 
transcription factors (Luciano and Wilson, 2000; Piluso et al., 2002; Luciano and 
Wilson, 2003; Tyagi et al., 2007; Vercauteren et al., 2008; Mazars et al., 2010).  In 
addition, HCF-1 influences gene expression by recruiting chromatin remodeling 
factors, such as the Sin3 histone deacetylase and the Set1/MLL1 histone 
methyltransferases (Wysocka et al., 2003; Yokoyama et al., 2004) to target gene 
promoters.  These two functions of HCF-1, co-regulation of transcription factors and 
recruitment of chromatin modifiers, are integrated and play a critical role in major 
cellular processes.  During the G1-S phase transition of the cell cycle, HCF-1 
associates with E2F1 and recruits the histone methyltransferases MLL and Set1 to 
E2F1 target gene promoters, thereby promoting H3K4 trimethylation and activation of 
gene expression at these promoters (Tyagi et al., 2007).  However, during the early G1 
phase of the cell cycle, HCF-1 associates with the repressive E2F4 transcription factor 
and recruits the histone deacetylase Sin3a, causing repression of E2F4-target genes 
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(Tyagi et al., 2007).  Similarly, HCF-1 associates with E2F1 and promotes E2F1 target 
gene activation after DNA damage by recruiting the MLL/Set1 histone 
methyltransferase complexes to the promoters of E2F1 target genes (Tyagi and Herr, 
2009).  Thus, HCF-1 regulates cellular functions by selectively associating with 
specific transcription factors and chromatin modifiers under particular cellular 
contexts.   
To further illustrate HCF-1’s role as a transcriptional co-regulator, in 
pluripotent embryonic stem cells, HCF-1 binds the zinc-finger transcriptional 
regulator Ronin to coordinate regulation of genes important for maintaining 
embryonic stem cell (ESC) pluripotency and self-renewal capacity (Dejosez et al., 
2008; Dejosez et al., 2010).  Overexpression of Ronin allows ESCs to continue to self-
renew in an undifferentiated state under conditions that normally promote ESC 
differentiation (Dejosez et al., 2008; Dejosez et al., 2010).   However, this phenotype 
is abolished when Ronin is no longer capable of binding HCF-1, indicating that HCF-
1 is essential for Ronin’s ability to maintain ESC pluripotency (Dejosez et al., 2010).   
Consistent with this observation, HCF-1 and Ronin occupy the promoters of many 
shared genes, including genes involved in transcription initiation, mTOR signaling and 
oxidative phosphorylation (Dejosez et al., 2010).  Precisely how Ronin and HCF-1 
affect gene expression in ESCs is still unclear.   
C. elegans HCF-1, mammalian HCF-1 and mammalian HCF-2 share structural 
homology in that all contain two highly conserved protein interaction domains 
common to all HCF family members: the N-terminal Kelch domain and the C-terminal 
fibronectin 3 repeat domain (Fn3) (Figure 1.1) (Liu et al., 1999; Lee and Herr, 2001).   
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However, in addition to these two domains, mammalian HCF-1 contains unique 
structural motifs, including an N-terminal basic region, a centrally-located repeat 
region, and a C-terminal acidic region (Figure 1.1).  The repeat region contains 
proteolytic cleavage sites necessary for the processing of full length HCF-1 into 
corresponding N-terminal and C-terminal polypeptides (Kristie and Sharp, 1993; 
Wilson et al., 1995).  These N-terminal and C-terminal fragments associate via non-
covalent interactions (Wilson et al., 2000).  Interestingly, these separate fragments of 
HCF-1 have unique functions with respect to regulating the cell cycle.  The N-terminal 
subunit of HCF-1 is required for G1-S phase progression, while the C-terminal 
fragment of HCF-1 is involved in M-phase progression (Goto et al., 1997; Julien and 
Herr, 2003, 2004).  Furthermore, the full length non-cleaved HCF-1 protein possesses 
functions distinct from those of the HCF-1 fragments (Vogel and Kristie, 2006).  The 
mechanism regulating the proteolysis of HCF-1 was recently discovered to be 
dependent on the O-linked-β-N-acetylglucosaminyl transferase (OGT) protein which 
modifies the HCF-1 N-terminal subunit and directly cleaves the full length HCF-1 
protein at its proteolytic cleavage sites (Capotosti et al., 2011; Daou et al., 2011).  
Besides O-GlcNAcylation, little is known about the post-translational modifications of 
HCF-1.  C. elegans HCF-1 undergoes phosphorylation (Wysocka et al., 2001) and 
mammalian HCF-1 contains acetylated lysine residues (Choudhary et al., 2009).  
However, the proteins that mediate these post-translational modifications and what 
their consequences may be still remains unknown.   
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Figure 1.1 Conservation of HCF-1 protein family members 
Mammalian HCF-1 (HsHCF-1) and HCF-2 (HsHCF-2), and C. elegans HCF-1 
(CeHCF-1) share conserved Kelch and Fibronectin 3 (Fn3) repeat domains.  The 
mammalian HCF-1 protein contains unique motifs, including a central proteolytic 
processing domain (HCF-1PRO) which is cleaved to generate multiple independent N-
terminal and C-terminal polypeptides which then associate non-covalently.  Figure 
modified from Wysocka and Herr, 2003. 
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Despite the striking structural differences between mammalian and C. elegans 
HCF-1, and the overall structural similarity between mammalian HCF-2 and C. 
elegans HCF-1 (Figure 1.1), C. elegans HCF-1 exhibits stronger functional homology 
to human HCF-1 than to human HCF-2.   While human HCF-1 and HCF-2, along with 
C. elegans HCF-1 are able to stabilize the VP16 complex, only human HCF-1 and 
C. elegans HCF-1 are able to promote VP-16 transcriptional activity (Liu et al., 1999; 
Lee and Herr, 2001).  Furthermore, loss of hcf-1 mimics the cell proliferation and 
histone phosphorylation defects found in mammalian cells lacking functional HCF-1 
(Lee et al., 2007).  These observations suggest that mammalian HCF-1 may share with 
C. elegans HCF-1 a functional role in determining lifespan as well. 
 
1.2 Forkhead box, Class O (FoxO) transcription factors 
The forkhead box, class O (FoxO) transcription factors play critical roles in 
longevity, metabolism, stress response, cell proliferation and apoptosis across species 
(Arden, 2008).  FoxO family members are highly conserved, from C. elegans to 
mammals, and are characterized by a conserved DNA-binding domain which 
recognizes a consensus binding sequence known as the DAF-16 Binding Element 
(Furuyama et al., 2000).  C. elegans and Drosophila contain a single FoxO gene, daf-
16 and dFoxO, respectively.  In contrast, mammals have four FoxO family members, 
FoxO1, FoxO3, FoxO4 and FoxO6.  As mediators of extensive cellular and 
physiological processes, FoxO proteins receive inputs from a variety of environmental 
signals and are subjected to a high degree of regulatory control.  In turn, FoxO 
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proteins activate or repress a broad range of genes to achieve the appropriate cellular 
response to environmental conditions.   
 
1.2.1 Conserved regulation of FoxO transcription factors 
A number of extracellular signals converge upon the FoxO transcription 
factors to modulate their activity.  The insulin/IGF-1 signaling (IIS) cascade represents 
one of the major inputs by which FoxO factors are regulated (Figure 1.2).  Genetic 
studies using C. elegans provided early evidence that DAF-16/FoxO factors are key 
downstream effectors of IIS (Lin et al., 1997; Ogg et al., 1997).  Upon binding of 
insulin/IGF-1 peptide ligands, the insulin/IGF-1 receptor is activated, 
autophosphorylated and phosphorylates cytoplasmic target proteins (Kloet and 
Burgering, 2011).  Phosphorylation of the insulin receptor substrate (IRS) proteins by 
the insulin receptor activates the highly conserved phosphoinositide 3-kinase (PI3K) 
cascade.   PI3K activation produces 3’phosphorylated phosphoinositides, which serve, 
in turn, to activate the protein kinase AKT/PKB, via phosphorylation by 
phosphoinositide-dependent protein kinase 1 (PDK1).  Activated AKT/PKB then 
phosphorylates FoxO.  Phosphorylation of FoxO prevents its nuclear translocation, 
thus rendering it inactive, whereas reduction in insulin signaling results in 
dephosphorylation of FoxO and activation of its transcriptional activity.  The IIS 
pathway is an extremely well-conserved mechanism of FoxO regulation, functioning 
in C. elegans and Drosophila as well as in mammals (Figure 1.2).   
Besides insulin/IGF-1 signaling, FoxO activity is regulated via 
phosphorylation by additional highly conserved kinases.  The stress-activated Jun-N-  
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Figure 1.2 The conserved insulin/IGF-1 signaling pathway affects longevity. 
The insulin/IGF-1 signaling pathway affects lifespan of diverse organisms.  In C. 
elegans, inactivation of daf-2, age-1, pdk-1, or akt-1/akt-2 results in lifespan extension 
that is dependent on daf-16.  In Drosophila, mutation of the insulin receptor (dInR), or 
of the insulin receptor substrate, known as Chico, extends lifespan, while 
overexpression of dFOXO extends lifespan.  And in mice, mutation of the insulin 
receptor (IR), IGF-1 receptor (IGF-1R), or insulin receptor substrate (IRS) extends 
lifespan.   
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terminal kinase (JNK) phosphorylates FoxO and promotes FoxO nuclear translocation 
in C. elegans, Drosophila and mammalian cells (Essers et al., 2004; Oh et al., 2005; 
Wang et al., 2005).  In Drosophila and C. elegans, this activation of FoxO by JNK 
promotes lifespan extension (Oh et al., 2005; Wang et al., 2005).  FoxO factors are 
also modulated by the conserved MST1 protein kinases.  Mammalian MST-1 
phosphorylates FoxO in response to oxidative stress, and thereby promotes FoxO 
nuclear translocation and cell death, while in C. elegans, the MST1 ortholog CST-1 
promotes longevity through activation of DAF-16/FoxO (Lehtinen et al., 2006).  
Finally, the energy responsive AMP-activated protein kinase (AMPK) phosphorylates 
DAF-16/FoxO, in both C. elegans and mammalian cells (Greer et al., 2007a; Greer et 
al., 2007b).  In mammalian cells, phosphorylation of FoxO by AMPK in response to 
nutrient deprivation activates FoxO transcriptional activity (Greer et al., 2007b), while 
in C. elegans, one method of lifespan-extension mediated by dietary restriction is 
dependent on AMPK activation of DAF-16/FoxO (Greer et al., 2007a).   
 Conserved regulation of FoxO transcription factors extends to nuclear FoxO 
co-factors as well.  β-catenin acts as a transcriptional co-activator downstream of the 
Wnt signaling pathway to regulate T-cell factor (TCF) mediated transcription.  In C. 
elegans, the β-catenin homolog bar-1 physically associates with DAF-16 and 
promotes activation of DAF-16/FoxO target genes (Essers et al., 2005), while in 
mammalian cells, β-catenin binds to FoxO and enhances FoxO transcriptional activity 
(Essers et al., 2005; Hoogeboom et al., 2008).  Finally, the conserved sirtuin family of 
protein deacetylases/ADP-ribosyltransferases represents nuclear co-factors of DAF-
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16/FoxO which modulate DAF-16/FoxO in multiple species in a highly coordinated 
fashion, and will be described in greater detail in Chapter 1.2.3. 
  
1.2.2 Cellular and tissue-specific functions of mammalian FoxO proteins 
 Given the central and highly conserved role that FoxO proteins play in the 
aging process, many studies have attempted to clarify the specific celluar and tissue-
specific functions of mammalian FoxOs.  Of the four mammalian FoxO proteins, 
FoxO1, FoxO3 and FoxO4 are similarly regulated by AKT-mediated phosphorylation 
and nucleo-cytosolic shuttling downstream of insulin/IGF-1 signaling (Brunet et al., 
1999; Guo et al., 1999; Kops et al., 1999; Nakae et al., 1999; Rena et al., 1999).  In 
contrast, FoxO6 is expressed predominantly in the nucleus, although it remains 
sensitive to the effects of AKT-mediated transcriptional repression (Jacobs et al., 
2003; van der Heide et al., 2005).  Due to the highly conserved nature of their DNA-
binding domain, all FoxO proteins exhibit similar binding specificity to their 
consensus DAF-16 binding element, or DBE, consisting of the sequence TTGTTTAC 
(Furuyama et al., 2000) .  In addition, mammalian FoxO proteins also recognize the 
insulin responsive sequence, consisting of the sequence TT(G/A)TTTC (Brunet et al., 
1999).  The shared DNA binding sequence of FoxO proteins allows these transcription 
factors to share in regulating their target genes, although some specificity of function 
is believed to be conferred by their somewhat varied expression patterns (Salih and 
Brunet, 2008).   
  As previously discussed, FoxO transcription factors receive regulatory input 
from multiple signaling pathways, and thus, are able to modulate cellular responses to 
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varying environmental conditions.  FoxO target genes are involved in regulating many 
critical cellular processes (Figure 1.3).  Activation of FoxO transcription factors, for 
instance due to reduced growth factor signaling or increased cellular stress conditions, 
leads to FoxO-mediated upregulation of genes which lead to cell cycle arrest (Ho et 
al., 2008).  FoxO proteins upregulate expression of the genes encoding the cyclin-
dependent kinase inhibitors, p21 and p27, and the retinoblastoma protein family 
member, p130, thus promoting G1/S phase arrest (Ho et al., 2008).  FoxO factors also 
upregulate the growth and DNA-damage response gene Gadd45a, and the cyclin gene 
cyclin G2, to promote G2/M phase cell cycle arrest (Ho et al., 2008).  FoxO 
transcription factor activation can also lead to apoptosis.  FoxO proteins upregulate the 
transcriptional expression of multiple pro-apoptotic Bcl-2 family members, such as the 
pro-apoptotic members Bim and Puma (van der Vos and Coffer, 2011).  The FoxO 
transcriptional target genes FasL and TRAIL also promote apoptosis by encoding 
ligands of cellular death receptors (van der Vos and Coffer, 2011).  As a result of their 
effects on cell cycle arrest and apoptosis, FoxO transcription factors play key roles in 
tumor suppression (Zhang et al., 2011a).  FoxO transcription factors are also central 
actors in regulating energy homeostasis.  In response to changes in nutrient 
availability, FoxO transcription factors regulate expression of genes involved in 
altering metabolism.  For example, FoxO promotes expression of the 
phosphoenolpyrvate carboxykinase and glucose-6 phophatase genes to promote 
hepatic gluconeogenesis, and the IGFBP1 gene to regulate IGF-1 bioavailability and 
insulin sensitivity (Gross et al., 2008).  This brief introduction highlights just a handful 
of the FoxO transcriptional targets identified, and serves to illustrate the key finding 
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that FoxO transcription factors act as master regulators of a multitude of cellular 
processes, including, but not limited to, cellular proliferation, apoptosis, metabolism, 
autophagy, stress resistance and cell differentiation (van der Vos and Coffer, 2011). 
While many FoxO target genes have been identified through cell culture 
studies, mouse models have corroborated the critical role that FoxO factors play in 
regulating cellular processes in multiple tissue types. Evidence from mouse models in 
which FoxO function has been perturbed supports the idea that FoxOs have both 
redundant and non-redundant functions in vivo.  FoxO1 was the first of the 
mammalian FoxOs to be knocked out in mice (Nakae et al., 2002).  FoxO1 null 
embryos die in utero at embryonic day 11 due to cardiovascular developmental defects 
(Furuyama et al., 2004; Hosaka et al., 2004).  In contrast, FoxO3 and FoxO4 
homozygous knockout mice are viable.  FoxO3 null mice, while viable, are 
characterized by female age-dependent infertility resulting from premature ovarian 
follicle depletion (Castrillon et al., 2003; Hosaka et al., 2004).  FoxO4 knockout mice 
are phenotypically normal (Hosaka et al., 2004). These results indicate that FoxO1 
plays a unique role in the development of the cardiovascular system (Hosaka et al., 
2004).  Interestingly, the first study looking at mice with conditional triple FoxO1, 
FoxO3, and FoxO4 knocked out in adulthood showed that these mice exhibit age-
dependent overproliferation of endothelial cells resulting in the development of 
hemangiomas, and ultimately death (Paik et al., 2007), indicating that FoxOs do share 
redundant functions as this phenotype was not seen in single FoxO mutants.  With the 
development of additional tissue-specific single, double and triple FoxO1, FoxO3, and 
FoxO4 knockout mice, we have discovered much about the redundancy of FoxO  
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Figure 1.3 FoxO factors modulate expression of genes involved in diverse  
   cellular processes. 
Mammalian FoxO transcription factors are regulated by multiple extracellular signals.  
When activated, FoxO proteins modulate the expression of genes involved in diverse 
cellular processes, allowing cells to respond to varying environmental stimuli.  
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factors in vivo.  FoxO1, FoxO3 and FoxO4 are all critically involved in maintaining 
the hematopoietic stem cell and neural stem cell pools (Miyamoto et al., 2007; 
Tothova et al., 2007; Paik et al., 2009), in regulating hepatic lipid metabolism and 
glucose production (Tao et al., 2011; Zhang et al., 2012), and in promoting 
cardiomyocyte survival in response to oxidative stress (Sengupta et al., 2011).  
Similarly, both FoxO1 and FoxO3 function in the immune system by inhibiting T-cell 
hyperactivation and promoting regulatory T-cell development (Lin et al., 2004; 
Kerdiles et al., 2010), and regulating B-cell proliferation and differentiation (Dengler 
et al., 2008; Hinman et al., 2009).  
 
1.2.2.1 The role of FoxO in the regulation of metabolism 
As downstream effectors of insulin-signaling, FoxOs play critical roles in 
regulating whole-body energy homeostasis.  Of the mammalian FoxO proteins, FoxO1 
has been most widely studied for its role in affecting metabolism.  In addition to the 
mentioned role of FoxO1 in promoting hepatic glucose production and lipid 
metabolism, FoxO1 is also involved in regulating skeletal muscle, adipose tissue and 
pancreatic β-cell function.  In skeletal muscle, FoxO1 is responsible for inhibiting 
skeletal muscle differentiation, promoting skeletal muscle atrophy, and mediating the 
switch between carbohydrate and fatty acid oxidation under hypoglycemic conditions 
(Furuyama et al., 2003; Kamei et al., 2004; Sandri et al., 2004; Bastie et al., 2005).    
FoxO1 also plays a role in inhibiting adipocyte differentiation (Nakae et al., 
2003).  Preadipocytes subjected to specific adipogenic stimuli are committed to 
undergo differentiation into mature adipocytes (Cristancho and Lazar, 2011).  The 
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differentiation program is induced by a transcriptional cascade that promotes the 
expression of genes associated with mature, functional adipocytes.  Of the many 
transcription factors involved in adipogenesis, peroxisome proliferator-activated 
receptor gamma (PPARγ) and CCAAT/enhancer-binding protein (C/EBP) –α, -β, and 
–δ are the principle factors driving adipogenesis  (Cristancho and Lazar, 2011).  
C/EBPβ and C/EBPδ expression is increased early after adipogenic stimulation, and 
they in turn transactivate the PPARγ and C/EBPα genes.  PPARγ and C/EBPα auto- 
and trans-regulate their own expression, further upregulating the transcription of their 
target genes during terminal differentiation of mature adipoctyes (Cristancho and 
Lazar, 2011).  FoxO1 inhibits differentiation of adipocytes by repressing the 
expression and transcriptional activity of PPARγ (Dowell et al., 2003; Armoni et al., 
2006; Fan et al., 2009).  In addition, FoxO1 also upregulates the cell cycle inhibitor 
p21, thus inhibiting the progression of the cell cycle which is necessary for early 
initiation of adipogenesis (Nakae et al., 2003).   
The role of FoxO1 in pancreatic β-cells is multi-faceted.    Pancreatic β-cells 
respond to increased circulating glucose by secreting insulin, which promotes the 
cellular uptake and storage of glucose, thus maintaining tight control of serum glucose 
levels.  Failure of pancreatic β-cell function is a key feature of diabetes (DeFronzo and 
Abdul-Ghani, 2011).  β-cell function is determined both by pancreatic β-cell mass and 
by the ability of β-cells to appropriately secrete insulin in response to elevated glucose 
levels.  The insulin/IGF-1 signaling pathway critically regulates insulin secretion and 
β-cell proliferation, and as such, disruption of this signaling pathway leads to the 
development of diabetes (Withers et al., 1998; Kulkarni et al., 1999; Kubota et al., 
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2000; Kulkarni et al., 2002; Xuan et al., 2002).  Mice lacking insulin receptor substrate 
2 (IRS-2) develop diabetes due to peripheral insulin resistance and failure of β-cell 
proliferation (Withers et al., 1998; Kubota et al., 2000).  IRS-2 knockout mice also 
exhibit reduced expression of the pancreatic duodenal homeobox 1 (Pdx1) 
transcription factor (Kitamura et al., 2002), which is essential for pancreatic 
development, β-cell differentiation and maintenance of β-cell function (Jonsson et al., 
1994; Offield et al., 1996; Ahlgren et al., 1998; Brissova et al., 2002; Johnson et al., 
2003).  Haploinsufficiency of FoxO1 in IRS2 knockout mice restores β-cell 
proliferation and Pdx1 expression, and prevents the development of diabetes 
(Kitamura et al., 2002).  Similarly, mice with heterozygous deletion of the insulin 
receptor also develop diabetes, exhibit reduced β-cell mass and reduced Pdx1 
expression, and these phenotypes are suppressed by haploinsufficiency of FoxO1 
(Nakae et al., 2002).  And in mice with β-cell-specific abalation of the PDK1 gene, 
which encodes a kinase acting downstream of the insulin/IGF-1 pathway, diabetes 
develops due to reduced β-cell mass (Hashimoto et al., 2006).  Haploinsufficiency of 
FoxO1 in β-cell-specific PDK1 knockout mice restores β-cell mass and glucose 
homeostasis (Hashimoto et al., 2006). These results suggest that the development of 
diabetes in mice with impaired insulin-signaling is largely due to FoxO1 activation.  In 
β-cells, FoxO1 inhibits Pdx1 expression by opposing FOXA2-mediated transcription 
of the Pdx1 gene (Kitamura et al., 2002).  FoxO1 also represses Pdx1 activity by 
affecting Pdx1 nuclear translocation (Kitamura et al., 2002; Kawamori et al., 2006).  
Importantly, transgenic expression of Pdx1 restores β-cell mass and function in 
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diabetic IRS-2 knockout mice (Kushner et al., 2002) similar to the effect of FoxO1 
haploinsufficiency.   
 In addition to inactivated insulin/IGF-1 signaling, pancreatic β-cell dysfunction 
can also result from exposure to a variety of stress-inducing stimuli (Evans et al., 
2002).  Activation of FoxO1 in β-cells appears to mediate many of the stress-
responses that lead to β-cell failure.  Exposure of β-cells to elevated fatty acids 
increases JNK-FoxO1 signaling leading to apoptosis. By decreasing FoxO1 activity, 
β-cells are protected from fatty-acid induced apoptosis (Martinez et al., 2008).  
Similarly, the inflammatory cytokine prostaglandin E2 (PGE2) activates JNK-FoxO1, 
leading to β-cell dysfunction as a result of FoxO1-mediated Pdx1 cytoplasmic 
translocation (Meng et al., 2009).  Glucocorticoid exposure results in β-cell failure, as 
well, by activating FoxO1, leading to inhibition of Pdx1 (Zhang et al., 2009b).   Thus, 
multiple lines of evidence suggest that inappropriate activation of FoxO1, either 
through cellular stress signaling pathways or through compromised insulin/IGF-1 
signaling, results in the repression of Pdx1 and consequent β-cell dysfunction.   
However, in contrast to the findings mentioned above, oxidative stress also 
promotes FoxO1 transactivation of the insulin gene transcription factors MafA and 
NeuroD, suggesting that FoxO1 may prevent oxidative stress induced β-cell failure 
(Kitamura et al., 2005).   It appears, then, that FoxO1 may play multiple roles in β-
cells based on specific cellular signals.   
More recently, the effects of FoxO1 on pancreatic β-cell function in vivo have 
been examined using mouse models with tissue-specific FoxO1 activation or ablation 
(Kim et al., 2012; Kobayashi et al., 2012).  Mice with expression of a constitutively 
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active form of FoxO1 in the hypothalamus and pancreas exhibited impaired glucose 
tolerance due, in part, to decreased glucose-stimulated insulin secretion (Kim et al., 
2012).  While previous studies indicated that FoxO1 activation in β-cells results in 
reduced cell proliferation, transgenic hypothalamic- and pancreas-specific FoxO1 
knockin mice had significantly increased number of islet cells, despite a significant 
decrease in Pdx1 mRNA levels, suggesting that there are compensatory mechanisms 
allowing for β-cell proliferation in the face of FoxO1-mediated reduction in Pdx1 
levels (Kim et al., 2012).   Consistent with the decrease in Pdx1 expression, islets of 
FoxO1 transgenic mice also contained less insulin (Kim et al., 2012).    
In contrast to the transgenic FoxO1 knockin mice, mice with pancreas- specific 
ablation of FoxO1 showed improved glucose tolerance and increased islet cell mass 
while on a high fat high sucrose diet (Kobayashi et al., 2012).   However, β-cell 
specific ablation of FoxO1 did not improve the glucose tolerance or islet mass of mice 
on a high fat high sucrose diet (Kobayashi et al., 2012).  These phenotypes were 
correlated with Pdx1 expression levels as pancreas-specific FoxO1 knockout mice 
showed elevated Pdx1 levels whereas β-cell specific FoxO1 knockout mice showed no 
change in Pdx1 expression.  The apparent differences between the pancreas-specific 
and β-cell specific FoxO1 knockout mice might be explained by the different temporal 
and spatial expression of the systems used to generate deletion of FoxO1 in these 
animals (Kobayashi et al., 2012).  Furthermore, when pancreas-specific or β-cell 
specific FoxO1 knockout mice were crossed with diabetic db/db mice lacking the 
leptin receptor, glucose intolerance increased and glucose-stimulated insulin secretion 
decreased (Kobayashi et al., 2012).  These observations run counter to the previous 
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findings in which haploinsufficiency of FoxO1 restored glucose homeostasis in 
multiple diabetic mouse models (Kitamura et al., 2002; Nakae et al., 2002; Hashimoto 
et al., 2006).  The role of FoxO1 in regulating pancreatic β-cell function thus appears 
quite complex. Elucidating the mechanisms underlying the differential effects of 
FoxO1 in pancreatic β-cells will be critical for the future development of novel 
therapeutics aimed at treating diabetes.   
 
1.2.3 Sirtuins as conserved FoxO regulators 
SIRT1/SIR-2.1 are members of the evolutionarily conserved sirtuin 
nicotinamide adenine dinucleotide (NAD
+
)-dependent family of protein 
deacetylases/ADP-ribosyltransferases.  Silent Information Regulator 2 (SIR2), the 
founding member of this family, was first identified in the budding yeast 
Saccharomyces cerevisiae as being involved in establishing transcriptional silencing at 
the mating-type loci (Ivy et al., 1986; Rine and Herskowitz, 1987).  Later, it was 
revealed that overexpression of SIR2 extends yeast replicative lifespan, whereas SIR2 
deletion shortens lifespan (Kaeberlein et al., 1999).  This phenotype is associated with 
SIR2’s role in suppressing the formation of detrimental extrachromosal ribosomal 
DNA circles (ERC) resulting from homologous recombination at these loci 
(Kaeberlein et al., 1999). Investigation of sir-2.1, the C. elegans homolog of yeast 
SIR2, demonstrated that overexpression of sir-2.1 could extend lifespan in this species 
as well (Tissenbaum and Guarente, 2001; Viswanathan et al., 2005; Berdichevsky et 
al., 2006).  Furthermore, overexpression of dSIR2 in Drosophila also extends lifespan, 
highlighting the conserved nature of sirtuin function in lifespan determination (Rogina 
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and Helfand, 2004).  In C. elegans, SIR-2.1 functions as a co-activator of DAF-
16/FoxO by associating with DAF-16/FoxO in the nucleus in a stress- and 14-3-3 
dependent manner (Berdichevsky et al., 2006).  Association of SIR-2.1 with DAF-
16/FoxO enhances DAF-16/FoxO transcriptional activity, thus promoting lifespan 
extension and stress-resistance (Berdichevsky et al., 2006).     
In mammals, seven members of the sirtuin family are present, SIRT1-7, each 
containing a highly conserved NAD
+
-binding domain and catalytic domain (Haigis 
and Sinclair, 2010).  However, these mammalian sirtuins exhibit differential 
subcellular localization patterns, and enzymatic activities (Table 1.1).  In particular, 
SIRT1 and SIRT2 exhibit both nuclear and cytoplasmic localization, whereas SIRT3, 
SIRT4 and SIRT5 reside in mitochondria, and SIRT6 is nuclear while SIRT7 is found 
in the nucleolus (Imai and Guarente, 2010).  Of the sirtuins, yeast Sir2, and 
mammalian SIRT1, SIRT2, SIRT3, SIRT5, SIRT6 and SIRT7 have shown NAD
+
-
dependent deacetylase activity (Imai et al., 2000; Onyango et al., 2002; North et al., 
2003; North et al., 2005), although SIRT5, SIRT6 and SIRT7 have very little 
deacetylase activity relative to SIRT1-3 (North et al., 2005).  SIRT4 and SIRT6 
function as ADP-ribosyltransferases (Liszt et al., 2005; Haigis et al., 2006; Michishita 
et al., 2008) and recently, SIRT5 was shown to function as a demalanoylase and 
desuccinylase (Du et al., 2011) which could explain the relatively weak or absent 
deacetylase activity exhibited by these sirtuins.  A growing number of sirtuin target 
proteins have been identified, and the functional importance of sirtuin-mediated 
enzymatic modification of these targets is an area of much interest (Haigis and 
Sinclair, 2010; Imai and Guarente, 2010).   
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Sirt1
Sirt2
Sirt3
Sirt4
Sirt5
Sirt6
Sirt7
Deacetylase, ADP-
ribosyltransferase
Deacetylase
Localization
Nucleus, Cytoplasm
Cytoplasm, Nucleus
Mitochondria
Mitochondria
Mitochondria
Nucleus
Nucleolus
Enzymatic activity
Deacetylase
Deacetylase
Deacetylase
ADP-ribosyltransferase
Deacetylase, Demalanoylase, 
Desuccinylase
Table 1.1  Enzymatic activity and localization of 
mammalian sirtuins.
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Figure 1.4 Sirtuins modulate DAF-16/FoxO transcription factor activity. 
C. elegans SIR-2.1 and mammalian SIRT1, members of the nicotinamide adenine 
dinucleotide (NAD
+
)-dependent family of protein deacetylases/ADP-
ribosyltransferases, form a protein complex with DAF-16/FoxO transcription factors, 
and affect DAF-16/FoxO transcriptional activity.  In C. elegans, SIR-2.1 activates 
DAF-16-mediated transcription of genes responsible for promoting stress resistance 
and longevity.  Mammalian SIRT1 directly deacetylates FoxO proteins, thus 
increasing FoxO DNA binding ability, and modulating FoxO transcriptional activity to 
affect cellular stress resistance and metabolism. 
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Of the seven sirtuins, SIRT1 has been most extensively studied both in vitro 
and in vivo.  After the discovery that SIR-2.1 functions in C. elegans to extend 
lifespan through activation of DAF-16, multiple groups showed that mammalian FoxO  
proteins are also targets of SIRT1 (Figure 1.4) (Brunet et al., 2004; Daitoku et al., 
2004; Motta et al., 2004; van der Horst et al., 2004).  SIRT1 directly deacetylates 
FoxO in a stress-dependent manner, thereby altering FoxO transcriptional activity by 
either repression or activation in a gene- and context-specific manner (Brunet et al., 
2004; Motta et al., 2004).  To explain the differential effects of SIRT1 in modulating 
FoxO activity, it has been postulated that SIRT1 acts to modify FoxO transcriptional 
responses to favor expression of cell cycle arrest genes while inhibiting apoptotic gene 
expression (Brunet et al., 2004).  What is known about FoxO acetylation is that it 
appears to inhibit the DNA-binding capability of FoxO (Matsuzaki et al., 2005; Tsai et 
al., 2007) while also increasing AKT-mediated phosphorylation of FoxO (Matsuzaki 
et al., 2005).  SIRT1 may have multiple effects on FoxO-mediated transcription by 
either increasing FoxO DNA binding capacity and promoting FoxO nuclear 
translocation, or by deacetylating histones around FoxO target genes, thereby 
inhibiting FoxO transactivation (Calnan and Brunet, 2008).  In addition to direct 
effects of SIRT1 on FoxO, there may also be indirect regulation of FoxO through 
SIRT1’s effects on FoxO co-factors.  Like FoxO, the transcriptional regulator 
peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) is deacetylated 
by SIRT1 resulting in increased activation of PGC-1α (Nemoto et al., 2005; Rodgers 
et al., 2005).  PGC-1α itself is an important co-activator for FoxO1 in regulating 
hepatic gluconeogenesis (Puigserver et al., 2003; Housley et al., 2009).  Therefore, it 
 26 
is possible that SIRT1 may modulate FoxO activity through deacetylating PGC-1α 
and/or other FoxO co-factors. 
More recently, the predominantly cytoplasmic sirtuin SIRT2 has also emerged 
as a critical FoxO deacetylase (Jing et al., 2007; Wang et al., 2007a; Wang and Tong, 
2009; Zhao et al., 2010).  In 3T3-L1 adipocytes, SIRT2 associates with, and 
deacetylates FoxO1, thereby causing increased FoxO1 nuclear localization and 
resulting in FoxO1 inhibition of adipocyte differentiation (Jing et al., 2007; Wang and 
Tong, 2009).  SIRT2 also deacetylates FoxO1 thus activating oxidative stress 
responses and preventing FoxO1-mediated autophagy (Wang et al., 2007a; Zhao et al., 
2010).  These findings highlight the diverse modes of FoxO regulation through 
deacetylation by sirtuins, and the complexity exhibited by the mammalian sirtuin-
FoxO regulatory interaction. 
 Given the conserved role of sirtuins in promoting longevity, many studies have 
examined the in vivo functions of SIRT1 in mammals.  SIRT1 null mice on an inbred 
genetic background have increased perinatal lethality and developmental defects, and 
those that survive to adulthood are small and sterile (McBurney et al., 2003).  Due to 
these complications, many studies of SIRT1 function in vivo have utilized transgenic 
mice.  In particular, SIRT1’s role in the regulation of metabolism has been extensively 
analyzed.  The interest in the metabolic functions of SIRT1 stem from the findings that 
caloric restriction, a highly effective method of lifespan extension in diverse 
organisms, is dependent on SIR2 homologs in yeast (Lin et al., 2000) and Drosophila 
(Rogina and Helfand, 2004).  While the exact role of sirtuins in mediating the 
longevity effects of caloric restriction continue to be debated (Haigis and Sinclair, 
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2010), SIRT1 clearly plays a role in regulating glucose homeostasis.  Transgenic mice 
overexpressing SIRT1 are leaner, with increased metabolic rate, and improved glucose 
tolerance relative to wildtype mice (Bordone et al., 2007).  Another strain of 
transgenic SIRT1 mice did not have increased metabolic rate or lower body weight, 
but did show improved glucose tolerance and were resistant to developing diabetes 
under conditions that promote insulin resistance (Banks et al., 2008).  In yet another 
study, transgenic SIRT1 mice had increased metabolic rates compared to control mice 
when fed a high fat diet, and were also protected from developing high fat diet-
induced hepatic steatosis and glucose intolerance (Pfluger et al., 2008).   Furthermore, 
mice overexpressing SIRT1 specifically in pancreatic β-cells exhibit enhanced insulin 
secretion in response to glucose, and thus impoved glucose tolerance (Moynihan et al., 
2005) while SIRT1 homozygous knockout mice have reduced circulating insulin 
levels (Bordone et al., 2006).  Finally, while wildtype mice respond to a calorie-
restricted diet by increasing physical activity, SIRT1 null mice do not (Chen et al., 
2005; Boily et al., 2008), and SIRT1 null mice also do not have an increased lifespan 
in response to caloric restriction (Boily et al., 2008), indicating that mammalian SIRT1 
is required for these phenotypes.  While these and other studies illustrate the beneficial 
effect of SIRT1 in regulating glucose homeostasis and the metabolic response to 
dietary manipulations, there are conflicting reports of the role that SIRT1 plays in 
specific tissues (Haigis and Sinclair, 2010).  Liver-specific SIRT1 knockout mice have 
been reported to exhibit both increased and decreased high fat diet-induced fatty liver 
disease (Chen et al., 2008a; Purushotham et al., 2009; Wang et al., 2010).  The reason 
for this discrepancy is unclear.  However, more recent studies looking at hepatic 
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overexpression of SIRT1 showed that these mice were protected from glucose 
intolerance and hepatic steatosis under conditions that promote insulin resistance (Li et 
al., 2011).  Thus, the overall conclusion from these studies is that SIRT1 promotes 
glucose homeostasis and ameliorates the effects of dietary and genetic conditions that 
promote insulin resistance. 
In addition to roles in metabolism, SIRT1 also protects against the 
development of age-related diseases, such as cancer (Firestein et al., 2008; 
Oberdoerffer et al., 2008; Wang et al., 2008b; Herranz et al., 2010), neurodegeneration 
(Araki et al., 2004; Qin et al., 2006; Kim et al., 2007; Donmez et al., 2010) and 
cardiovascular disease (Alcendor et al., 2007; Zhang et al., 2008).  However, despite 
the beneficial effects of SIRT1 on metabolism and age-related pathologies, 
overexpression of SIRT1 does not appear to extend mammalian lifespan (Herranz et 
al., 2010), although SIRT1 null mice do live shorter than wildtype mice (Boily et al., 
2008; Li et al., 2008b).  Further studies of SIRT1 mouse models are needed to 
determine whether SIRT1 affects longevity in mammals, and whether any of the 
beneficial effects of SIRT1 are mediated by FoxO.  Thus far, the evidence supports a 
role for SIRT1 in promoting metabolic adaptation to adverse conditions, and 
preventing the onset of age-related diseases.   
 
1.3 HCF proteins as potential conserved regulators of FoxO transcription 
 factors in mammals. 
 Given that HCF proteins are highly conserved between C. elegans and 
mammals, and that C. elegans HCF-1 acts as a transcriptional repressor of DAF-16, I 
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hypothesize that HCF-1 and/or HCF-2 function as co-repressors of mammalian FoxO 
transcription factors.  Furthermore, as SIR-2.1 acts upstream of C. elegans HCF-1 in 
modulating DAF-16 activitiy, I hypothesize that mammalian HCF proteins interact 
with mammalian sirtuins to co-regulate FoxO transcriptional activity.  Thus, by 
regulating the activity of FoxO factors, which are critically involved in modulating 
expression of diverse cellular target genes, mammalian HCF proteins are likely to be 
required for appropriate control of FoxO-mediated processes, including apoptosis, 
cellular proliferation, and metabolism. 
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CHAPTER 2 
 
HCF-1 AND SIRT1, THE MAMMALIAN HOMOLOGS OF TWO 
EVOLUTIONARILY CONSERVED LONGEVITY DETERMINANTS, 
COLLABORATE TO REGULATE FOXO
1 
 
2.1 ABSTRACT   
The conserved DAF-16/FoxO transcription factors and SIR-2.1/SIRT1 
deacetylases are critical for diverse biological processes, particularly longevity and 
stress response, and complex regulation of DAF-16/FoxO by SIR-2.1/SIRT1 is central 
to appropriate biological outcomes.  Caenorhabditis elegans Host Cell Factor 1 (HCF-
1) is a longevity determinant previously shown to act as a co-repressor of DAF-16.  
Genetic analyses have shown that hcf-1 acts downstream of sir-2.1 to influence 
lifespan and oxidative stress response in C. elegans, while gene expression profiling 
has revealed a striking 80% overlap between the DAF-16 target genes responsive to 
hcf-1 mutation and sir-2.1 overexpression.  Analogous to its role in regulating DAF-
16/SIR-2.1 target genes in C. elegans, mammalian HCF-1 and HCF-2 also repress the 
expression of FoxO/SIRT1 target genes.  Protein-protein association studies 
demonstrate that SIRT1 and HCF-1/HCF-2 form protein complexes with mammalian 
FoxOs, highlighting the conservation of this regulatory relationship.  Furthermore, 
SIRT1 acts to promote the deacetylation of HCF-1, but not HCF-2, at lysine residues 
located in a region unique to mammalian HCF-1.  Our findings uncover a conserved 
interaction between the key longevity determinants SIR-2.1/SIRT1 and HCF-1, and 
provide new insights into the complex regulation of FoxO proteins.   
 
                                                 
1
 Chapter 2 is modified from Rizki G, Iwata TN, Li J, Riedel CG, Picard CL, Jan M, Murphy CT, and 
Lee SS, PLoS Genetics (2011). 
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2.2 INTRODUCTION  
The Insulin/Insulin-like Growth Factor-1(IGF-1) signaling (IIS) cascade is one 
of the most highly conserved and best characterized longevity pathways in eukaryotes.  
When stimulated, the insulin/IGF-1-like receptors initiate a kinase cascade that leads 
to the phosphorylation, and cytoplasmic retention of the main downstream effectors, 
Forkhead box, Class O (FoxO) transcription factors.  Reduction in IIS signaling leads 
to the dephosphorylation of FoxO, allowing nuclear translocation and transcriptional 
activation of FoxO (Burgering and Kops, 2002; Kenyon, 2010).  The C. elegans FoxO 
ortholog DAF-16, as well as the Drosophila, mouse, and human FoxO transcription 
factors are all critical for longevity, metabolism, and stress response (Kenyon et al., 
1993; Lin et al., 1997; Giannakou et al., 2004; Hwangbo et al., 2004; Arden, 2008; 
Kappeler et al., 2008; Wang et al., 2008a; Willcox et al., 2008; Li et al., 2009; Yuan et 
al., 2009), suggesting that the mechanisms underlying FoxOs’ ability to affect 
physiology are highly conserved across species.  Indeed, much of our understanding of 
FoxO regulation comes from studies done on C. elegans DAF-16.  When activated, 
DAF-16/FoxO selectively regulates the transcription of a large number of genes which 
cumulatively act to elevate stress resistance, alter metabolic and developmental 
responses, improve immunity, and extend lifespan (Lee et al., 2003; McElwee et al., 
2003; Murphy et al., 2003; Halaschek-Wiener et al., 2005).  To integrate many 
different environmental stimuli and coordinate proper transcriptional responses, DAF-
16/FoxO activity must be tightly controlled.  DAF-16/FoxO activity is known to be 
regulated by post-translational modifications, nuclear/cytoplasmic translocation and 
association with transcriptional co-regulators.  Little is known about the interplay 
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between DAF-16/FoxO and its nuclear regulators and how these multiple factors 
coordinately act on DAF-16/FoxO to ensure proper transcriptional outcomes.   
Host Cell Factor-1 (HCF-1) belongs to a family of highly conserved HCF 
proteins and acts as a nuclear co-repressor of DAF-16 (Lee and Herr, 2001; Li et al., 
2008a).  Inactivating hcf-1 robustly extends lifespan and confers oxidative stress 
resistance in a daf-16-dependent manner in C. elegans.  In the nucleus, HCF-1 
associates with DAF-16 and limits its access to a subset of target gene promoters (Li et 
al., 2008a).  C. elegans HCF-1 shares high structural homology with two mammalian 
counterparts, HCF-1 and HCF-2 (Lee and Herr, 2001).  Although mammalian HCF-1 
has been studied extensively, HCF-2 functions remain largely unknown.  Mammalian 
HCF-1 was originally identified as a binding partner of the Herpes Simplex Virus 
VP16 transcription factor (Gerster and Roeder, 1988).  Apart from VP16, HCF-1 has 
been shown to associate with a number of transcription factors to stimulate or repress 
their transactivation properties (Lu et al., 1997; Gunther et al., 2000; Lu and Misra, 
2000; Piluso et al., 2002; Wysocka et al., 2003; Tyagi et al., 2007).  HCF-1 is an 
important regulator of cellular proliferation as it promotes progression through 
multiple phases of the cell cycle via assembling transcriptional complexes to modulate 
E2F transcription factor activities (Julien and Herr, 2004; Tyagi et al., 2007).  Whether 
mammalian HCF proteins function as conserved FoxO regulators has yet to be 
determined.    
SIR-2.1, the C. elegans homolog of the yeast NAD+-dependent protein 
deacetylase Sir2p, is an important DAF-16 co-factor.  SIR-2.1 is thought to activate 
DAF-16 in conferring longevity as well as stress resistance (Tissenbaum and 
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Guarente, 2001; Berdichevsky et al., 2006; Wang et al., 2006).  Heat stress stimulates 
the physical association of SIR-2.1 with DAF-16 via the scaffolding protein 14-3-3, 
which promotes the transactivation of DAF-16 (Berdichevsky et al., 2006; Wang et 
al., 2006).  Overexpression of Sir2 homologs in worms, yeast and flies extends 
lifespan (Kaeberlein et al., 1999; Tissenbaum and Guarente, 2001; Rogina and 
Helfand, 2004; Berdichevsky et al., 2006), emphasizing the evolutionarily conserved 
role of Sir2 in longevity determination.  In mammals, SIRT1 associates with and 
directly deacetylates FoxO1, 3, and 4 in a stress-dependent manner (Brunet et al., 
2004; Daitoku et al., 2004; Motta et al., 2004; Yang et al., 2005).  This high degree of 
conservation suggests that other factors involved in SIR-2.1/DAF-16 interactions in C. 
elegans may be functionally conserved in mammals as well.   
Importantly, we have shown that C. elegans hcf-1 acts downstream of sir-2.1 
to regulate daf-16, and thereby modulate lifespan and oxidative stress response in C. 
elegans (Rizki et al., 2011).  In addition, we showed that HCF-1 and SIR-2.1 regulate 
a common subset of DAF-16 target genes important for ensuring longevity and stress 
response (Rizki et al., 2011).  In this study, we sought to examine whether the two 
conserved DAF-16/FoxO nuclear regulators, HCF-1 and SIRT1 interact in a conserved 
manner in mammals.  We demonstrated that both mammalian HCF-1 and HCF-2 
affect the expression of several SIRT1/FoxO transcriptional targets, and both HCF-1 
and HCF-2 physically associate with FoxO3 and SIRT1.  Furthermore, we find that 
SIRT1 acts to specifically target HCF-1, and not HCF-2, for deacetylation at a number 
of lysine residues located within the basic region of the HCF-1 protein.  Our findings 
uncover a new regulatory mechanism between the critical longevity determinants 
 34 
DAF-16/FoxO and SIR-2.1/SIRT1, and implicate an important role of HCF-1 in aging 
and age-related diseases in diverse organisms.  
 
2.3 RESULTS 
2.3.1 Mammalian HCF-1 and HCF-2 regulate the expression of a subset of 
 FoxO target genes. 
In C. elegans, HCF-1 functions downstream of SIR-2.1 to repress the activity 
of DAF-16 (Li et al., 2008a; Rizki et al., 2011).  HCF-1 belongs to a highly conserved 
family of proteins (Julien and Herr, 2003; Wysocka and Herr, 2003; Tyagi et al., 
2007).  In mammals, two homologs of HCF-1 are present: HCF-1 and HCF-2.  
Mammalian HCF-1 plays a role in transcriptional regulation and cell cycle 
progression.  The functions of HCF-2 remain unknown.  SIRT1, the mammalian 
homolog of SIR-2.1, is known to interact with and deacetylate the DAF-16 homolog 
FoxO3 and thereby affects FoxO3 transcriptional activity (Brunet et al., 2004; Motta 
et al., 2004).  Given that HCF-1, DAF-16 and SIR-2.1 are highly conserved between 
C. elegans and mammals, we tested whether mammalian homologs of HCF-1 could 
affect the transcription of FoxO- and SIRT1- co-regulated target genes.  Since 
mammalian HCF-1 is required for proper cell cycle progression, we employed a 
transient knockdown approach by transfecting siRNA duplexes targeting the HCF-1 
gene into INS-1 rat insulinoma cells.  The HCF-1 siRNA effectively reduced HCF-1 
mRNA and HCF-1 protein levels (Figure 2.1A-B), and is specific as it did not affect 
the expression of HCF-2 mRNA (Figure 2.1A).  We examined the expression of p27, 
Bim, Gadd45a, and IGFBP1, four FoxO target genes that are affected by SIRT1 
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deacetylation of FoxO (Brunet et al., 2004; Motta et al., 2004).  Depletion of HCF-1 
resulted in a significant increase in the level of Bim, Gadd45a, and IGFBP1 
transcripts, but did not affect p27 expression (Figure 2.2A).  We observed similar 
results using a second HCF-1-targeting siRNA duplex (Figure 2.2A).  We next 
assessed whether HCF-2 could also affect FoxO target gene expression.  Similar to 
HCF-1 knockdown, cells treated with HCF-2 siRNA exhibited increased expression of 
Gadd45a and no change in p27 (Figure 2.2B).  However, unlike the case with HCF-1, 
cells depleted of HCF-2 did not show any significant changes in Bim, or IGFBP1 
transcripts (Figure 2.2B).  Our data reveal that HCF proteins negatively regulate the 
expression of a subset of FoxO and SIRT1 transcriptional target genes.    Furthermore, 
HCF-1 appears to play a more substantial role in regulating FoxO target genes relative 
to HCF-2.  The observation that HCF-1 and HCF-2 have specific effects on a subset of 
FoxO targets tested is also consistent with our findings in C. elegans suggesting HCF-
1 to be a specificity factor for DAF-16/FoxO.   
 
2.3.2 Mammalian HCF-1 and HCF-2 physically associate with FoxO3 and 
SIRT1. 
In C. elegans, HCF-1 is able to physically associate with both DAF-16 and 
SIR-2.1.   We therefore hypothesized that mammalian HCF-1 may also be involved in 
physical associations with FoxO3 and SIRT1.  To examine the physical interactions 
between these proteins, we transfected HEK293T cells with plasmids encoding either 
Flag-tagged FoxO3 or Flag-tagged SIRT1.  We then performed co-
immunoprecipitation experiments with these cell lysates by using Flag-antibody 
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 Figure 2.1 Specific knockdown of HCF-1 and HCF-2 by siRNA. 
INS-1 cells transfected with HCF-1 (A,B) or HCF-2 (C) siRNA were analyzed by RT-
qPCR and Western blotting.  (A) Two HCF-1 targeting siRNAs were used to 
knockdown HCF-1.  siHCF-1 #1 treatment resulted in a moderate increase in HCF-2 
expression.  HCF-2 was not affected by siHCF-1 #2.  (B) HCF-1 siRNA substantially 
reduced HCF-1 protein levels. ** indicates a non-specific band. HCF-1 is known to be 
proteolytically processed and is detected as multiple bands on SDS-PAGE.  (C) 
Knockdown of HCF-2 did not affect HCF-1 expression.  Values are normalized to the 
level of β-actin.  The mean normalized mRNA level for each gene in sicontrol treated 
cells was set to 1.  The data represented are pooled from three independent 
experiments and are represented as mean +/- SEM.  * denotes a p-value <0.05. 
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Figure 2.2 Mammalian HCF-1 and HCF-2 regulate the expression of FoxO 
  target genes. 
INS-1 cells treated with HCF-1 (A) or HCF-2 (B) siRNA compared to control siRNA.  
mRNA levels of Bim, Gadd45a, p27,and IGFBP1 were quantified using RT-qPCR 
and normalized to the level of β-actin.  The mean normalized RNA level for each gene 
in sicontrol treated cells was set to 1.  The data represented are pooled from three 
independent experiments and are represented as mean +/- SEM.  * denotes a p-value 
<0.05 relative to sicontrol. 
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conjugated agarose beads.  Both FoxO3 and SIRT1 were found to interact with the 
endogenous mammalian HCF-1 protein (Figure 2.3A-B).  We also tested whether the 
closely related HCF-2 protein could also physically interact with FoxO3 and SIRT1.  
Like HCF-1, HCF-2 was also present in a protein complex with FoxO3 and SIRT1 
(Figure 2.3C-D).  These results indicate that the physical associations between HCF-1 
family members, DAF-16/FoxO and SIR-2.1/SIRT1 are highly conserved between C. 
elegans and mammals. 
 
2.3.3 SIRT1 promotes HCF-1 deacetylation. 
 Since SIRT1 is a protein deacetylase and is well known to modulate substrate 
activity by deacetylating its targets, we assessed whether SIRT1 affects HCF-1 or 
HCF-2 acetylation status.  We immunoprecipitated HCF-1 or HCF-2 from HEK293T 
cells overexpressing HA-tagged versions of these proteins, and then probed for 
acetylation using a pan-acetyl-lysine antibody.  Under normal culture conditions, we 
detected a low level of HCF-1 and HCF-2 acetylation.  Treatment of the cells with 
nicotinamide, a known SIRT1 inhibitor, dramatically increased the levels of HCF-1 
acetylation (Figure 2.4A).  However, unlike HCF-1, HCF-2 was not affected by 
nicotinamide treatment (Figure 2.4A).  To further confirm that the increased 
acetylation was due to SIRT1 inhibition, we transfected HEK293T cells with plasmids 
encoding the HA-HCF-1 protein as well as short-hairpin RNA targeting the human 
SIRT1 gene (Figure 2.4B).  Immunoblotting revealed that in cells transfected with the 
SIRT1 shRNA, SIRT1 expression was reduced compared to the control shRNA-  
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Figure 2.3 Mammalian HCF-1 and HCF-2 physically associate with FoxO3 
  and SIRT1. 
(A, B) HEK293T cells were transfected with plasmids encoding Flag-FoxO3 (A) or 
Flag-SIRT1 (B).  Cell lysates were collected 48 hours later and incubated with anti-
Flag-conjugated agarose beads.  Immunoprecipitated protein complexes were analyzed 
by western blot using anti-HCF-1, anti-FoxO3 or anti-SIRT1 antibodies. * denotes a 
non-specific band. (C, D) HEK293T cells were co-transfected with plasmids encoding 
HA-HCF2 and either Flag-FoxO3 (A) or Flag-SIRT1 (B).  Cell lysates were collected 
48 hours later and incubated with either anti-Flag- or anti-HA-conjugated agarose 
beads.  Immunoprecipitated protein complexes were analyzed by western blot using 
anti-HCF-2, anti-FoxO3 or anti-SIRT1 antibodies.   
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Figure 2.4 SIRT1 promotes deacetylation of HCF-1, but not HCF-2. 
(A) HEK293T cells overexpressing HA-HCF1 or HA-HCF2 were treated with 10mM 
nicotinamide (NAM) for 6 hours.  HCF-1 or HCF-2 was immunoprecipitated using 
anti-HA-conjugated agarose beads and analyzed by western blot using an anti-acetyl-
lysine antibody. (B) HEK293T cells were co-transfected with HA-HCF1 (left) or HA-
HCF2 (right) and a shRNA plasmid targeting either the control luciferase gene or 
SIRT1.  HCF-1 or HCF-2 was immunoprecipitated and analyzed as in (A).  
Knockdown of SIRT1 was confirmed by immunoblotting with anti-SIRT1 antibody.  
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transfected cells.  In cells with decreased levels of SIRT1 protein, HCF-1 acetylation 
was increased (Figure 2.4B, left panel), indicating that SIRT1 is responsible for HCF-
1 deacetylation.  By contrast, HCF-2 acetylation was not affected by SIRT1 
knockdown (Figure 2.4B, right panel).  Thus, our results show that SIRT1 specifically 
targets HCF-1, and not HCF-2, for deacetylation.   
 
2.3.4 The basic region of mammalian HCF-1 undergoes deacetylation in 
 response to increased sirtuin activity. 
We next sought to determine whether a specific domain of the HCF-1 protein 
is targeted for deacetylation by sirtuins.  We utilized a series of human HCF-1 
truncation mutant expression constructs that have previously been used to dissect the 
functions of specific HCF-1 domains (Wilson et al., 1997) (Figure 2.5A).  We 
assessed whether each truncated form of HCF-1 was acetylated, and if so, whether the 
acetylation status of that fragment was affected by the sirtuin inhibitor nicotinamide.  
The HCF-1 domains we analyzed included the full-length protein (FL); a region 
containing the N-terminal Kelch domain (N380, residues 1-380); a region including 
the Kelch domain as well as the basic region (N1011, residues 1-1011); and a C-
terminal fragment including the Fibronectin 3 repeat domain (C600, residues 1436-
2035).  Each fragment also included an N-terminal HA epitope tag.  We transfected 
each expression plasmid into HEK293T cells, and then treated the cells with 
nicotinamide for 6 hours.   After immunoprecipitation of the fragments, we performed 
western blot analysis to detect acetylation levels.  As previously observed, full length 
HCF-1 was acetylated and this acetylation was robustly increased in the presence of 
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nicotinamide.  The N380 fragment of HCF-1 including only the Kelch domain, 
however, showed no acetylation, with or without nicotinamide.  In contrast, the region 
of HCF-1 including both the Kelch domain and the basic region, N1011, was clearly 
acetylated, and acetylation was dramatically increased with nicotinamide treatment, 
similar to that of the full-length HCF-1 protein.  The C-terminal fragment of HCF-1 
(C600) was also clearly acetylated, but showed little change with nicotinamide 
treatment.  Thus, we conclude that the region of HCF-1 sensitive to sirtuin-mediated 
deacetylation involves the basic region of HCF-1.   
 
2.3.5 Lysine 813 of HCF-1 is deacetylated by sirtuins. 
Recent proteomic analysis has identified mammalian HCF-1 to be acetylated at 
a number of lysine residues (Choudhary et al., 2009).  Of the five lysines identified to 
be acetylated, two reside within the basic region; lysine 813 (K813) and lysine 836 
(K836) (Choudhary et al., 2009).  To determine if one or both of these sites was 
sensitive to sirtuin-mediated deacetylation, we mutated each of these residues to either 
arginine, which conserves the charged nature of lysine, but is unable to be acetylated, 
or to glutamine, which is non-charged and mimics the acetylated form of lysine.  We 
then repeated our analysis of the nicotinamide sensitivity of these mutated HCF-1 
proteins.  Interestingly, mutation of K813 to either arginine or glutamine reduced, but 
did not abolish, the acetylation induced by nicotinamide (Figure 2.6).  By contrast, 
mutation of K836 to either arginine or glutamine did not reduce the acetylation levels  
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Figure 2.5 The basic region of HCF-1 is targeted for deacetylation by sirtuins. 
(A) Diagram of HCF-1 deletion mutants used to map the region of HCF-1 targeted for 
deacetylation by sirtuins, as determined by nicotinamide (NAM) sensitivity.  FL = full 
length HCF-1; N380 = HCF-1 residues 1-380; N1011 = HCF-1 residues 1-1011; C600 
= HCF-1 residues 1436-2035.  Full length and deletion mutants were tagged with the 
HA epitope at the N-terminus. (B) HCF-1 truncation mutants were overexpressed in 
HEK293T cells.  Cells were treated with 10mM NAM for 6 hours.  HCF-1 was 
immunoprecipitated using anti-HA-conjugated agarose beads and analyzed by western 
blot using an anti-acetyl-lysine antibody. 
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Figure 2.6 Sirtuins target lysine 813 of HCF-1 for deacetylation. 
(A) Wildtype (wt) and mutant HCF-1 proteins in which lysine (K) 813 or 836 were 
mutated to arginine (R) or glutamine (Q) were overexpressed in HEK293T cells.  
Cells were treated with nicotinamide (NAM).  HCF-1 was immunoprecipitated using 
anti-HA-conjugated agarose beads and analyzed by western blot using an anti-acetyl-
lysine antibody.  (B) Quantification of the relative fold change in NAM-induced 
acetylation of wt and mutant forms of HCF-1, as quantified from the blot shown in 
(A). 
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of this HCF-1 mutant, and in fact, mutation of K836 to arginine slightly increased 
nicotinamide-induced acetylation.  These results indicate that K813 represents one of 
the lysines deacetylated by sirtuins, and indicates that additional, as yet to be 
identified, lysines are also targeted for deacetylation by sirtuins. 
 
2.4 DISCUSSION 
 The highly conserved FoxO transcription factors are master regulators of 
diverse biological processes (van der Horst and Burgering, 2007) and as such, their 
transcriptional activities are tightly controlled (Essers et al., 2005; Berdichevsky et al., 
2006; Berman and Kenyon, 2006; Lehtinen et al., 2006; Wolff et al., 2006; Li et al., 
2008a).  Although a number of different transcriptional co-factors of DAF-16/FoxO 
have been identified, little is known about how they functionally interact to fine-tune 
DAF-16/FoxO activity.  In this study, we expanded upon our previous identification of 
the nuclear DAF-16 co-repressor HCF-1, and find that mammalian HCF-1 acts as an 
integral conserved component of the regulatory network involving SIR-2.1/SIRT1 and 
DAF-16/FoxO.  We have shown that, as in C. elegans, mammalian HCF-1 likely 
functions downstream of SIRT1 to regulate a distinct subset of FoxO target genes.   
  Considering the high conservation of DAF-16/FoxO-related pathways, it is 
not surprising that the regulatory relationship among HCF-1, SIR-2.1 and DAF-16 we 
uncovered previously in worms turns out to be conserved in mammals.  Our findings 
in mammalian cells are nevertheless very exciting as they implicate the HCF proteins 
to be key components linking FoxO and SIRT1, two critical master regulators of 
physiology in mammals.  Our results indicate that while both mammalian HCF-1 and  
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Figure 2.7 Conserved regulation of FoxO by HCF-1 and SIRT1 
In C. elegans, HCF-1 forms a complex with SIR-2.1, and together they regulate the 
transcriptional activity of DAF-16/FoxO.  We find that this functional relationship is 
conserved in mammals, where SIRT1 is able to bind and deacetylate HCF-1 while 
HCF-1 is able to bind FoxO, and affect FoxO transcriptional target gene expression.  
Our results highlight HCF proteins to be key components of the regulatory network 
linking SIR-2.1/SIRT1 and DAF-16/FoxO in diverse organisms.  
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HCF-2 are able to interact with SIRT1 and FoxO3, HCF-1 has a greater effect on 
FoxO target gene expression.  Interestingly, while both mammalian HCF-1 and HCF-2 
as well as C. elegans HCF-1 are able to support the formation of the Herpes Simplex 
Virus VP16-transcriptional complex, only mammalian and C. elegans HCF-1 are able 
to promote VP16 transcriptional activity (Lee and Herr, 2001).  Thus, it appears that 
the evolutionarily conserved functions of HCF proteins are retained in mammalian 
HCF-1.  Alternatively, HCF-1 and HCF-2 likely have tissue-specific functions and are 
regulated differently under different cellular contexts.   
While our data indicate that parallel regulatory mechanisms are shared 
between C. elegans and mammalian HCF-1, they also suggest the modes of regulation 
between HCF-1, SIRT1, and FoxO in mammals are likely more complex than what is 
observed in C. elegans.  We note that in the case of the mammalian FoxO target genes 
Bim and IGFBP1, HCF-1 and SIRT1 appear to affect FoxO target gene expression in a 
similar manner (Figure 2.2A and (Brunet et al., 2004; Motta et al., 2004)), and thus 
would appear to act in concert rather than antagonistically.  On the other hand, HCF-1 
and SIRT1 appear to have antagonistic effects on the FoxO target gene Gadd45a.  It is 
important to keep in mind that in mammals, SIRT1 regulation of FoxO transcription 
factors is complex; in some instances SIRT1 acts as a repressor and in other cases as 
an activator of FoxO (Brunet et al., 2004; Motta et al., 2004), while in C. elegans the 
predominant role of SIR-2.1 is as an activator of DAF-16.  It is likely that in 
mammals, the interplay between SIRT1 and HCF-1 results in collaborative as well as 
antagonistic effects on FoxO transcriptional activity in a gene- and context-dependent 
manner.  Future genome-wide studies examining the effects of HCF-1 on 
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FoxO/SIRT1-regulated gene expression will provide further insights into the 
relationship between HCF-1 and SIRT1.      
In mammals, SIRT1 directly deacetylates FoxO proteins and modifies their 
transcriptional activities.  Our data indicate that SIRT1, and likely other sirtuins, 
facilitate the deacetylation of HCF-1 as well.  Interestingly, the region of HCF-1 
which we found to be deacetylated in response to sirtuins is not conserved between C. 
elegans and mammals (Figure 1.1).  Consistent with this finding, we are unable to 
detect deacetylation of C. elegans  HCF-1 by SIR-2.1 (G. Rizki, unpublished data).  
These results suggest that HCF-1 has evolved to include additional regulatory modules 
that can be acted upon by its co-evolving modifiers.   
Mammalian SIRT1 is also able to deacetylate and activate the FoxO co-
activator PGC1α (Puigserver et al., 2003; Nemoto et al., 2005; Rodgers et al., 2005).  
It seems likely, then, that SIRT1 affects multiple FoxO responses by deacetylating 
FoxO and specific FoxO co-regulators to achieve activation and/or repression of the 
appropriate target genes.  Furthermore, while our analyses indicate that SIRT1 
promotes HCF-1 deacetylation, we note that the increased HCF-1 acetylation observed 
with nicotinamide treatment was dramatically greater than that observed with SIRT1 
knockdown (Figure 2.4) suggesting that other sirtuins in addition to SIRT1 function to 
modify HCF-1.  It will be interesting in the future to determine which, if any, other 
sirtuins modulate HCF-1 acetylation, and whether this action is due to direct 
deacetylation of HCF-1 by sirtuins, or indirectly through other 
acetyltransferases/deacetylases.   
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Besides being acetylated, HCF-1 is known to be post-translationally modified 
by phosphorylation and O-GlcNAcylation (Wysocka et al., 2001; Wang et al., 2007b).  
These various post-translational modifications may be dynamically regulated by each 
other, allowing for specific control of HCF-1 function in response to environmental 
cues.  Interestingly, recent analyses indicate that the O-GlcNAc transferase (OGT) 
catalyzes the addition of O-GlcNAc moieties on the mammalian HCF-1 protein at 
multiple serine and threonine residues located in and adjacent to the basic region of 
HCF-1 (Capotosti et al., 2011).  OGT binding to the basic region appears to enhance 
its interaction with HCF-1, thus promoting its ability to proteolytically cleave the full 
length HCF-1 protein at the proteolytic processing domain (Capotosti et al., 2011).  
Our results point to the intriguing possibility that the basic region represents a major 
site of post-translational modification of HCF-1, and suggests possible cross-talk 
between acetylation and O-GlcNAcylation in determining functional outcomes of 
HCF-1.  Our analyses also indicate that lysine 813 of human HCF-1 is one, but not the 
only, lysine targeted for sirtuin-mediated deacetylation.  Future studies aimed at 
identifiying the other lysines targeted by sirtuins will facilitate examination of the 
functional outcomes resulting from acetylation/deacetylation of HCF-1.   
As our study suggests, regulation of DAF-16/FoxO activity likely entails a 
well-coordinated response by SIR-2.1/SIRT1 and HCF-1 that is achieved through 
highly specific interactions with additional co-factors and/or distinctive protein 
modifications.  We have also shown that 14-3-3 proteins likely physically associate 
with HCF-1 in C. elegans (Rizki et al., 2011).  Previous studies in C. elegans indicate 
that 14-3-3 proteins act as bridging molecules that bring SIR-2.1 and DAF-16 into a 
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protein complex in the nucleus (Berdichevsky et al., 2006; Wang et al., 2006).  
Whether 14-3-3 proteins are also involved in the regulation of FoxO by SIRT1 and 
HCF in mammals remain to be investigated.   
In conclusion, our findings establish a novel link between two evolutionarily 
conserved DAF-16/FoxO regulators.  This study expands our understanding of the 
complex role that nuclear factors play in determining the specificity of DAF-16/FoxO 
activity.  These results further implicate HCF-1 as a novel factor that may affect 
mammalian aging and age-related pathologies through interactions with SIRT1 and 
FoxO.   
 
2.5 MATERIALS AND METHODS 
2.5.1 Plasmids, shRNA and siRNA for mammalian cells 
Flag-FoxO3 and Flag-SIRT1 were obtained from Addgene and have been 
described previously (Brunet et al., 2004).  The HCF-1 deletion mutants were kindly 
provided by W. Herr (Wilson et al., 1997).  The plasmids encoding HA-HCF-1 and 
HA-HCF-2 were generated by cloning the human HCF-1 and HCF-2 cDNA into the 
vector pCMV-HA (Clontech).  PCR mutagenesis was utilized to generate the HA-
HCF-1 K813R, K813Q, K836R and K836Q mutants.  The plasmid encoding the short-
hairpin RNA targeting the human SIRT1 gene was generously provided by W.L. Kraus 
(Zhang et al., 2009a).  The plasmid encoding shRNA targeting the firefly luciferase 
gene was generously provided by L. Qi (Cornell University).  siRNA duplexes 
directed against rat HCF-1 and HCF-2 were purchased from Dharmacon and targeted 
the following sequences: siHCF-1 #1:  5’-GGAAGAGACTGAAGGCAAA-3’; 
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siHCF-1 #2: 5’-AGAACAACATTCCGAGGTA-3’; siHCF-2: 5’- 
GGGAATGGTTGAATATGGA-3’.  Non-targeting control siRNA was also from 
Dharmacon.  Cells were collected 48 hours post-transfection, or treated for an 
additional 6 hours with nicotinamide (10mM, Sigma).   
 
2.5.2 Cell culture and Transfection  
HEK293T cells were maintained in DMEM containing 4.5g/L glucose and 
10% bovine calf serum and were transfected with the indicated plasmids using 
calcium phosphate.  INS-1 cells were maintained in RPMI-1640 medium containing 
11.1mM glucose, 10% fetal bovine serum, 1mM pyruvate, 10mM HEPES, and 50µM 
2-mercaptoethanol.  INS-1 cells were transfected with siRNA at a concentration of 
10nM using Lipofectamine RNAiMax (Invitrogen).  siRNA transfections were 
performed twice, 24 hours apart, and cells were collected 24 hours after the second 
transfection. 
 
2.5.3 Reverse-transcription coupled quantitative PCR (RT-qPCR): 
RNA was isolated from mammalian cells using Trizol reagent and was reverse-
transcribed using Superscript III First-Strand kit (Invitrogen).  cDNAs were analyzed 
by quantitative-PCR using the SYBR Green system on a Roche LightCycler 480 real 
time PCR machine and quantified relative to a standard curve.  β-actin was used as an 
internal control.  The following primers were used: β-actin forward: 5’- 
CTAAGGCCAACCGTGAAAAG-3’; β-actin reverse: 5’-
AACACAGCCTGGATGGCTAC-3’; HCF-1 forward: 5’-
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GCTGGAAAAGCTCCTGTCAC-3’; HCF-1 reverse: 5’- 
CACTCATCTGTGGGTTGCTG-3’; HCF-2 forward: 5’-
TTGAAAGCAGAGCAATGGTG-3’; HCF-2 reverse: 5’- 
AGTCGGGTACGTCTGCATTT-3’; Bim forward: 5’- 
GCCCCTACCTCCCTACAGAC-3’; Bim reverse: 5’- 
CAGGTTCCTCCTGAGACTGC-3’; p27 forward: 5’- 
GTGGACCAAATGCCTGACTC-3’; p27 reverse: 5’- 
TTCTGTTCTGTTGGCCCTTT-3’; Gadd45a forward: 5’- 
GCAGAGCTGTTGCTACTGGA-3’; Gadd45a reverse: 5’- 
TGTGATGAATGTGGGTTCGT-3’; IGFBP1 forward: 5’- 
CTGCCAAACTGCAACAAGAA-3’; IGFBP1 reverse: 5’- 
TTCCCACTCCATGGGTAGAC-3’ 
 
2.5.4 Immunoblotting and Immunoprecipitations 
For co-immunoprecipitation experiments, HEK293T cells were transfected 
with the indicated plasmids.  48 hours after transfection, cells were lysed in lysis 
buffer (50mM Tris-HCl pH 8.0, 100mM NaCl, 2mM EDTA, 1% TritonX-100, 10mM 
NaF, 1mM sodium orthovanadate, 1mM PMSF, 10mM nicotinamide, 1mM 
trichostatin A, and Roche complete protease inhibitor cocktail).  Cell extracts were 
incubated with either Flag- or HA-conjugated agarose beads (Sigma) overnight at 4°C.  
Beads were washed five times in lysis buffer and eluted by boiling in SDS sample 
buffer.   Immunoprecipitates were analyzed by western blotting using the following 
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antibodies: anti-HA (Covance), anti-FoxO3 (Upstate), anti-SIRT1 (gift from W.L. 
Kraus), anti-HCF-1 (Bethyl Labs).   
 
2.5.5 Acetylation of HCF-1 and HCF-2 
HA-tagged HCF1 was expressed and immunoprecipitated from HEK293T 
cells as described above.  Acetylation was determined by western blotting for 
acetylated-lysine residues using an anti-acetyl-lysine antibody (Cell Signaling).   
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CHAPTER 3 
 
THE TRANSCRIPTIONAL CO-REGULATOR HCF-1 PROMOTES PDX1 
EXPRESSION, AND IS REQUIRED FOR INS-1 β-CELL SURVIVAL, 
PROLIFERATION AND GLUCOSE-STIMULATED INSULIN SECRETION
2
 
 
3.1 ABSTRACT 
The transcriptional co-activator HCF-1 plays critical roles in promoting cell 
cycle progression in multiple mammalian cell types, but its role in modulating 
pancreatic β-cell function has not been investigated.  We examined the phenotypes of 
INS-1 pancreatic β-cells in which HCF-1 was depleted by siRNA.  Reducing HCF-1 
expression resulted in decreased INS-1 β-cell proliferation, increased INS-1 β-cell 
death, and reduced glucose-stimulated insulin secretion.   HCF-1 is a known co-
activator of the E2F1 transcription factor, and loss of E2F1 results in pancreatic β-cell 
dysfunction and reduced expression of the pancreatic β-cell transcription factor Pdx1.  
E2F1 and HCF-1 form a protein complex in INS-1 β-cells, and HCF-1 promotes Pdx1, 
and Pdx1 targets’, gene expression.  Chromatin immunoprecipitation experiments 
revealed that HCF-1 and E2F1 co-localize to the Pdx1 promoter.  These results 
indicate that HCF-1 represents a novel transcriptional regulator of Pdx1 and is 
critically important for maintaining pancreatic β-cell function. 
 
                                                 
2
 I, together with SS Lee, conceived the experiments and analyzed the data contained in Chapter 3.  I 
performed all of the experiments with the exception of the co-immunoprecipitation experiment (Figure 
3.4) which was done by M Mierzejewski.    
 57 
3.2 INTRODUCTION 
Diabetes develops due to a deficiency in circulating insulin caused by 
pancreatic β-cell destruction and/or impaired β-cell function.  In type 1 diabetes, 
pancreatic β-cells are selectively destroyed resulting in reduced β-cell mass, while in 
type 2 diabetes, loss of insulin-secretory ability as well as β-cell apoptosis lead to 
defects in glucose homeostasis (Mathis et al., 2001; DeFronzo and Abdul-Ghani, 
2011).  Understanding the factors responsible for maintaining β-cell mass and β-cell 
function is, therefore, a key step in developing therapeutics to prevent the 
development of diabetes. 
The transcriptional regulator host cell factor-1 (HCF-1) plays critical roles in 
cell cycle progression (Wilson et al., 1997; Julien and Herr, 2003), DNA-damage 
induced apoptosis (Tyagi and Herr, 2009) and stem cell pluripotency (Dejosez et al., 
2008).  HCF-1 largely functions as a scaffolding protein assembling appropriate 
transcriptional complexes at target gene promoters and bridging interactions between 
transcription factors and chromatin remodeling factors (Wysocka et al., 2003; 
Yokoyama et al., 2004; Tyagi et al., 2007; Tyagi and Herr, 2009).  To date, no studies 
have examined whether HCF-1 may be involved in modulating β-cell function.   
Recently, HCF-1 was implicated to function as a novel repressor of FoxO 
transcription factors in mammals (Rizki et al., 2011).  FoxO proteins are major 
downstream effectors of insulin/IGF-1 signaling and are known to affect pancreatic β-
cell function.  Genetic disruption of the insulin/IGF-1 signaling pathway leads to β-
cell failure and the development of diabetes (Withers et al., 1998; Kulkarni et al., 
1999; Kubota et al., 2000; Kulkarni et al., 2002; Xuan et al., 2002; Hashimoto et al., 
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2006).  Haploinsufficiency of FoxO1 restores β-cell proliferation and islet cell mass, 
and prevents the development of diabetes in both Pdk1 and IRS2 mutant mice 
(Kitamura et al., 2002; Hashimoto et al., 2006),  indicating that the diabetic phenotype 
of these mice is largely due to FoxO1 activation.  In β-cells, FoxO1 inhibits the 
expression of the pancreatic duodenal and homeobox 1 (Pdx1) gene, a critical 
transcription factor, essential for pancreatic development, β-cell differentiation and 
maintenance of β-cell function (Jonsson et al., 1994; Offield et al., 1996; Ahlgren et 
al., 1998; Brissova et al., 2002; Johnson et al., 2003).  FoxO1 opposes FoxA2-
mediated transcription of the Pdx1 gene (Kitamura et al., 2002) and also represses 
Pdx1 activity by affecting Pdx1 nuclear translocation (Kitamura et al., 2002; 
Kawamori et al., 2006).  Importantly, transgenic expression of Pdx1 restores β-cell 
mass and function in diabetic IRS-2 knockout mice (Kushner et al., 2002), similar to 
the effect of FoxO1 haploinsufficiency (Kitamura et al., 2002).   
In addition to regulating FoxO transcription factors, HCF-1 acts as a co-
activator of the cell cycle regulator E2F1, thus promoting G1-to-S phase progression 
(Tyagi et al., 2007).  Recent studies also implicate E2F1 in the maintenance of 
pancreatic β-cell function.  E2F1 null mice exhibit decreased pancreatic islet cell 
proliferation, impaired glucose-stimulated insulin secretion and reduced Pdx1 
expression (Fajas et al., 2004).   E2F1 also acts as a transcriptional activator of the 
Kir6.2 gene, which encodes a subunit of the ATP-sensitive potassium channel 
responsible for coupling membrane depolarization and insulin release to glucose 
metabolism (Annicotte et al., 2009). 
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Thus, we wondered whether HCF-1, which is known to interact with both 
FoxO and E2F1 transcription factors, may also be involved in regulating pancreatic β-
cell function.  In this study, we analyzed the function of HCF-1 in the INS-1 
pancreatic β-cell line.  Our analyses identified HCF-1 as a critical factor essential for 
β-cell survival and glucose-stimulated insulin secretion, and a co-activator of the Pdx1 
gene.     
 
3.3 RESULTS 
3.3.1 Depletion of HCF-1 increases apoptosis and reduces INS-1 β-cell 
 proliferation 
Previous studies have indicated the requirement for HCF-1 in cell cycle 
progression (Wilson et al., 1997; Julien and Herr, 2003).  However, a role for HCF-1 
specifically in pancreatic β-cells has not been established.  We thus characterized the 
growth of INS-1 β-cells in which HCF-1 levels were reduced by siRNA.  HCF-1 
siRNA targeting four distinct regions (si#1, #2, #3, #4) of the HCF-1 mRNA were 
transfected into INS-1 cells and cell numbers monitored over time.  Of the four HCF-1 
siRNAs utilized, three exhibited effective knockdown of HCF-1 protein levels (si#1, 
#3, #4) (Figure 3.1A).  Four days after siRNA transfection, these three HCF-1 siRNA 
treated cell populations exhibited significantly less growth compared to control siRNA 
treated cells (Figure 3.1B).  The single HCF-1 siRNA (si#2) which did not reduce 
HCF-1 protein levels correspondingly did not produce a reduction in cell growth.  The 
results indicate that knockdown of HCF-1 correlates with a reduction in β-cell 
population over time.  
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The reduced number of cells observed after HCF-1 siRNA treatment could 
result from either increased apoptosis and/or reduced cell proliferation.  To test 
whether apoptosis was increased in the HCF-1 siRNA-treated cells, we examined 
caspase-3 cleavage.  We observed elevated levels of cleaved caspase-3 in the cell lines 
treated with the same HCF-1 siRNA duplexes that produced reductions in cell growth 
(si#1, #3, #4), while the single HCF-1 siRNA (si#2) which did not affect HCF-1 
protein levels or cell growth showed no activation of caspase-3 (Figure 3.1C).  Thus, 
loss of HCF-1 reduces β-cell populations due to increased apoptosis.  These results are 
consistent with our previous finding that knockdown of HCF-1 results in significant 
upregulation of the pro-apoptotic FoxO target gene, Bim (Rizki et al., 2011).  We next 
tested whether HCF-1 is required for cell proliferation by analyzing BrdU 
incorporation in β-cells depleted of HCF-1.  Using the three HCF-1 siRNAs (si#1, #3, 
#4) which showed effective knockdown, we observed that HCF-1 siRNA-treated cells 
had significantly less BrdU incorporated into their DNA (Figure 3.1D), indicating a 
failure in cell cycle progression, as has previously been shown in other mammalian 
cell types (Julien and Herr, 2003).  Whether the cells that failed to progress through S 
phase are undergoing apoptosis or are in cell cycle arrest awaits further analysis.  Our 
results suggest that HCF-1 is required for INS-1 β-cell growth by promoting both cell 
survival and cell proliferation.   
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Figure 3.1  HCF-1 is required for proliferation and survival of INS-1 β-cells.   
(A) Western blot analysis of HCF-1 protein levels from INS-1 cells transfected twice 
with control or four different HCF-1 siRNAs. (B) Cell growth curves of INS-1 cells 
treated with control or HCF-1 siRNA.  X-axis depicts days after the first siRNA 
transfection.  Experiment was done twice with similar results.  Data shown are from 
one representative experiment and expressed as mean +/- SEM for each time point. 
*denotes a p-value <0.05 relative to sicontrol (Student’s t-test). (C) Western blot 
analysis showing caspase-3 activation in cells from (B), at four days after the first 
siRNA transfection.  (D) BrdU incorporation assay of cells treated with HCF-1 
siRNA, three days after the first siRNA transfection.  Experiment was performed 
twice with similar results.  Data shown are from one representative experiment, and 
are expressed as the mean and 95% confidence interval. *denotes a p-value <0.001 
relative to sicontrol (Chi-squared test).  At least 400 cells per condition were counted.   
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3.3.2 HCF-1 is required for glucose-stimulated insulin secretion in INS-1 β-cells 
Given that HCF-1 is essential for survival and proliferation of INS-1 β-cells, 
we were interested in testing whether HCF-1 also affects these cells’ functional ability 
to secrete insulin in response to glucose.  INS-1 β-cells transfected with control siRNA 
exhibited a robust insulin secretion response when stimulated with high (16.7 mM) vs 
low (3mM) glucose, as determined by ELISA analysis.  HCF-1 siRNA-treated cells 
(si#1 and si#3), by contrast, did not increase insulin secretion in response to high 
glucose, indicating that HCF-1 is required for glucose-stimulated insulin secretion in 
the INS-1 β-cell model (Figure 3.2A).  We then examined whether the reduced insulin 
secretion phenotype might arise from an overall reduction in insulin content in these 
cells.  Indeed, analysis of the intracellular insulin content showed that HCF-1 
knockdown cells have reduced levels of insulin (Figure 3.2B), indicating that the 
reduction in secreted insulin may be due to the overall decrease in the cellular insulin 
pool.  However, since the reduction in intracellular insulin levels appeared modest, 
additional defects associated with insulin secretion likely also contribute to the greatly 
impaired ability of the HCF-1 siRNA-treated cells to produce extracellular insulin in 
response to high glucose.  To test whether overexpression of HCF-1 could result in 
increased insulin secretion, we took advantage of an inducible lentiviral 
overexpression vector to produce stable cell lines which overexpress HCF-1 in 
response to doxycycline (Figure 3.3A).  However, we did not observe an enhanced 
insulin secretion phenotype in response to HCF-1 overexpression (Figure 3.3B).  This 
result implies that, while HCF-1 is essential for appropriate insulin biosynthesis and 
secretion in response to glucose, the levels of HCF-1 in these cells is not limiting. 
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Figure 3.2 HCF-1 is required for insulin biosynthesis and secretion. 
(A) Glucose-stimulated insulin secretion analysis of cells treated with HCF-1 siRNA.  
Insulin secretion determined by insulin ELISA and normalized to total cellular protein.  
Results shown are pooled from three independent experiments, and represent mean +/- 
SEM. * denotes a p-value <0.05 relative to sicontrol (Student’s t-test).  (B) Cellular 
insulin content analysis of cells treated with HCF-1 siRNA.  Insulin content 
determined by insulin ELISA and normalized to total cellular protein.  Results shown 
are pooled from three independent experiments, and represent mean +/- SEM.  * 
denotes a p-value <0.05 relative to sicontrol (Student’s t-test).   
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Figure 3.3 HCF-1 overexpression does not increase insulin secretion. 
(A) Western blot analysis of HA-tagged HCF-1 in the inducible HCF-1 
overexpression cell line.  Cells were treated with vehicle or 200ng/ml of doxycycline 
for 24 hours.  (B) Glucose-stimulated insulin secretion analysis of INS-1 cells with 
induced overexpression of GFP or HA-HCF1.  Results shown are pooled from four 
independent experiments, and represent the mean +/- SEM. 
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3.3.3 HCF-1 physically interacts with FoxO1 and E2F1 
C. elegans HCF1 and mammalian HCF-1 proteins are able to physically 
interact with FoxO transcription factors and repress FoxO transcriptional activity (Li 
et al., 2008a; Rizki et al., 2011).  HCF-1 also acts as a co-activator of the E2F1 
transcription factor (Tyagi et al., 2007).   Loss of E2F1 (Fajas et al., 2004; Annicotte et 
al., 2009) or activation of FoxO1 (Kitamura et al., 2002; Hashimoto et al., 2006; 
Buteau et al., 2007) results in reduced β-cell proliferation and reduced glucose-
stimulated insulin secretion.  Therefore, we wondered whether HCF-1 affects β-cell 
phenotypes through interactions with FoxO1 or E2F1.  We thus assessed whether 
HCF-1 physically associates with either FoxO1 or E2F1 in INS-1 cells.  We induced 
overexpression of a doxycycline-inducible HA-tagged HCF-1 protein, and 
immunoprecipitated HCF-1 using HA-antibody conjugated beads.  We were able to 
clearly detect both endogenous FoxO1, as well as endogenous E2F1, 
immunoprecipitating with HCF-1 (Figure 3.4).   Therefore, in INS-1 β-cells HCF-1 is 
found in protein complexes with both FoxO1 and E2F1, suggesting that HCF-1 acts 
with FoxO1 and/or E2F1 to regulate β-cell function.   
 
3.3.4 Pdx1 expression is reduced in HCF-1 knockdown cells 
Both E2F1 and FoxO1 affect the expression of the β-cell transcription factor 
Pdx1, which is itself critical for the development and function of pancreatic β-cells.  In 
mature β-cells, Pdx1 promotes insulin gene transcription and insulin secretion 
(Ohlsson et al., 1993; Brissova et al., 2002) and is required for β-cell survival 
(Johnson et al., 2003; Johnson et al., 2006) and β-cell proliferation in response to 
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systemic insulin resistance (Kulkarni et al., 2004).  E2F1 inactivation reduces Pdx1 
expression (Fajas et al., 2004), whereas FoxO1 activation represses Pdx1 expression 
(Kitamura et al., 2002; Buteau et al., 2007).   As HCF-1 knockdown phenocopies Pdx1 
inactivation, we wondered whether HCF-1 may in fact cooperate with E2F1 or FoxO1 
to regulate expression of Pdx1.  We therefore tested whether Pdx-1 mRNA and protein 
levels were altered in cells with reduced HCF-1 levels.  Indeed, we found that HCF-1 
siRNA-treated cells showed significant reductions in levels of Pdx1 protein (Figure 
3.5A) and mRNA transcripts (Figure 3.5B).  In addition, the Pdx1 target genes Ins1 
and Ins2 also showed significantly reduced expression (Figure 3.5B), correlating well 
with our observation of reduced intracellular insulin levels in cells depleted of HCF-1 
(Figure 3.2B).  These results suggest that loss of HCF-1 leads to diminished Pdx1 
activity through reductions in Pdx1 expression, which likely contribute to reduce 
proliferation, survival, and insulin secretion in β-cells.   
 
3.3.5 HCF-1 and E2F1 are enriched at the Pdx1 promoter 
A well known function of HCF-1 is to regulate gene expression by assembling 
chromatin modifiers and transcription factors into appropriate complexes at target 
gene promoters (Wysocka et al., 2003; Tyagi et al., 2007).  During the G1-to-S phase 
transition, HCF-1 associates with E2F1 at E2F1 target gene promoters, and recruits the 
MLL family of histone methyltransferases to promote expression of E2F1 target genes 
(Tyagi et al., 2007; Tyagi and Herr, 2009).  HCF-1-mediated regulation of 
transcriptional activity can also occur through interactions with proteins away from 
target gene promoters.  C. elegans HCF-1 represses the transcriptional activity of the  
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Figure 3.4 HCF-1 physically interacts with FoxO1 and E2F1. 
INS-1 cells with stable integration of pInducer20-HA-HCF1 were treated with 1ug/ml 
doxycycline for 24 hours to induce expression of HA-HCF1.  HA-HCF1 was 
immunoprecipitated with anti-HA-conjugated agarose beads, and analyzed by western 
blot with the indicated antibodies. 
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Figure 3.5 HCF-1 regulates expression of Pdx-1. 
(A) Western blot analysis of Pdx-1 protein levels in HCF-1 knockdown cells. (B) RT-
qPCR analysis of Pdx1, Ins1 and Ins2 transcript levels in HCF-1 knockdown cells.  
The mean normalized RNA level for each gene in sicontrol treated cells was set to 1.  
The data shown are pooled from three independent experiments and are represented as 
mean +/- SEM.  * denotes a p-value <0.05 relative to cells treated with sicontrol 
siRNA (Student’s t-test).   
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C. elegans FoxO homolog by binding to it, thus preventing it from localizing to the 
promoters of its target genes (Li et al., 2008a).   Given that HCF-1 forms a complex 
with both FoxO1 and E2F1 in β-cells (Figure 3.4), it is possible that HCF-1 affects the 
ability of either E2F1 or FoxO1 transcription factors to regulate expression of Pdx1.   
We therefore performed chromatin immunoprecipitation (ChIP) experiments to assess 
whether HCF-1 represses FoxO1 localization to the Pdx1 promoter, or, alternatively, 
whether HCF-1 binds to the Pdx1 promoter in association with E2F1.   
FoxO1 has been shown to compete with FoxA2 for binding to the consensus 
forkhead binding sequence located in the highly conserved Pdx1 homology 2 (PH2) 
region of the mouse Pdx1 promoter (Kitamura et al., 2002).  Examination of the 
proximal promoter region of the rat Pdx1 promoter revealed an additional consensus 
forkhead binding sequence located 186 bp upstream of the transcription start site.   We 
performed ChIP analysis to determine FoxO1 enrichment at both of these locations, 
with or without HCF-1 knockdown.  As a negative control, we examined FoxO1 
localization to a non-coding region of chromosome 3 which lacks FoxO binding sites.  
We did not detect enrichment of FoxO1 at any of these regions, either under basal or 
HCF-1 knockdown conditions, as compared to the isotype-matched IgG control 
(Figure 3.6A).  These results indicate that FoxO1 binding is not increased by depletion 
of HCF-1.  Therefore, HCF-1 likely does not inhibit FoxO1 transcriptional repression 
of Pdx1. 
Next we examined whether HCF-1 and E2F1might be enriched at the Pdx1 
promoter.  While E2F1 localization to the Pdx1 promoter has not been previously 
examined, E2F1 is known to bind sites predominantly located in the proximal 
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promoter of its target genes, and near to CpG islands (Bieda et al., 2006).  The 
proximal promoter of the rat Pdx1 gene contains a highly conserved CpG island (Park 
et al., 2008) as well as a sequence (TTCGCGG) located 168 bp upstream of the 
transcription start site resembling the consensus E2F1 binding element (TTTXGCGC) 
(Tao et al., 1997).  We therefore wondered whether an HCF-1/E2F1 complex might 
localize to the Pdx1 promoter, thus promoting Pdx1 expression.  Interestingly, we 
found that HCF-1 enrichment at the Pdx1 promoter was significantly higher than at the 
non-coding region of chromosome 3, and comparable to that observed at the known 
HCF-1/E2F1 target gene cyclin A2 (Tyagi et al., 2007) (Figure 3.6B).  HCF-1 siRNA 
treatment reduced HCF-1 occupancy at both the Pdx1 and cyclin A2 promoters, 
indicating the specificity of HCF-1 binding at these promoters (Figure 3.6B).   
Examination of E2F1 promoter localization also revealed significant enrichment of 
E2F1 at both the cyclin A2 promoter as well as at the Pdx1 promoter, indicating that 
HCF-1 and E2F1 are both localized to the proximal promoter of Pdx1 (Figure 3.6C).  
E2F1 enrichment, in contrast to HCF-1, was not significantly affected by HCF-1 
knockdown (Figure 3.6C), consistent with previous studies indicating that HCF-1 is 
recruited by E2F1 to E2F1 target gene promoters (Tyagi et al., 2007).  These results 
indicate that HCF-1 and E2F1 may indeed cooperate to promote Pdx1 gene regulation.  
HCF-1 might generally promote E2F1 transcriptional activity in pancreatic β-cells.  
Consistent with this possibility, we also observe reduced expression of the E2F1 
transcriptional target gene Kir6.2 in HCF-1 knockdown cells (Figure 3.7).    
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Figure 3.6 HCF-1 occupies the Pdx1 promoter 
INS-1 cells treated with HCF-1 siRNA or control siRNA were subjected to chromatin 
immunoprecipitation assays using antibodies directed against (A) HCF-1, (B) E2F1, 
(C) FoxO1 or isotype-matched rabbit IgG.  Immunoprecipitated DNA was quantified 
using qPCR and calculated as percent of input DNA.  Results shown are pooled from 
three independent experiments and represent the mean +/- SEM.  FoxO1 was not 
enriched at either the PH2 region (Pdx1 PH2) or at the proximal promoter region of 
Pdx1 (Pdx1 prox) relative to the IgG control.  HCF-1 and E2F1 enrichment at the 
Pdx1 and cyclin A2 promoters was significantly greater than at the negative control 
region (chrIII) (* denotes a p-value <0.05, Student’s t-test).  Knockdown of HCF-1 
reduced HCF-1 enrichment at the Pdx1 and cyclin A2 promoters whereas E2F1 
enrichment was not affected by HCF-1 knockdown (n.s. = not significant).  Cyclin A2 
is a known E2F1 target and was included as a control.   
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Figure 3.7 HCF-1 knockdown reduces expression of E2F1 target genes. 
RT-qPCR analysis of Kir6.2 and cyclin A2 transcript levels in cells treated with HCF-
1 siRNA #1.  The mean normalized RNA level for each gene in sicontrol treated cells 
was set to 1.  The data shown are pooled from three independent experiments and are 
represented as mean +/- SEM.  * denotes a p-value <0.05 relative to sicontrol 
(Student’s t-test). 
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3.4 DISCUSSION 
Here we have shown that the transcriptional co-regulator HCF-1 is required for 
survival, proliferation and glucose-stimulated insulin secretion in the INS-1 β-cell line.  
Previous studies have highlighted the importance of HCF-1 in regulating cell cycle 
progression (Wilson et al., 1997; Julien and Herr, 2003; Tyagi et al., 2007).  We were, 
therefore, not surprised to observe reduced proliferation in INS-1 β-cells depleted of 
HCF-1.  In addition to decreased cell proliferation, we also observe increased cell 
death resulting from HCF-1 knockdown.  This is consistent with our previous finding 
that HCF-1 represses expression of the pro-apoptotic factor Bim (Rizki et al., 2011) 
which itself promotes pancreatic β-cell death (McKenzie et al., 2009; Santin et al., 
2011).  Thus, it is likely that loss of HCF-1 in vivo will result in reduced β-cell mass, a 
key feature of diabetes (Donath and Halban, 2004).   
We have also identified the β-cell transcription factor Pdx1 as a transcriptional 
target of HCF-1.  Pdx1 is required for maintenance of β-cell function by promoting 
insulin gene transcription and secretion (Ohlsson et al., 1993; Brissova et al., 2002), β-
cell survival (Johnson et al., 2003; Johnson et al., 2006) and β-cell proliferation 
(Kulkarni et al., 2004).  Loss of Pdx1 expression results in reduced β-cell mass, 
reduced pancreatic insulin content, and reduced glucose-stimulated insulin secretion 
(Ahlgren et al., 1998; Brissova et al., 2002), which are phenotypes we observe with 
reduced HCF-1 expression.  Importantly, human PDX1 mutations are associated with 
the development of diabetes (Stoffers et al., 1997; Stoffers et al., 1998; Macfarlane et 
al., 1999).  Thus, as a co-activator of Pdx1, and as a repressor of Bim gene expression, 
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HCF-1 represents a novel β-cell factor implicated in affecting diabetes development 
and progression.   
We have previously identified HCF-1 as a transcriptional co-repressor of FoxO 
transcription factors (Salih and Brunet, 2008; Rizki et al., 2011).  As a major 
downstream effector of insulin-signaling, FoxO1 prevents β-cell proliferation under 
reduced insulin-signaling conditions by repressing transcription of Pdx1 (Kitamura et 
al., 2002).  Consistent with a role for HCF-1 as a transcriptional co-repressor of 
FoxO1, we observe physical interactions between HCF-1 and FoxO1, and decreased 
levels of Pdx1 when HCF-1 is depleted.  However, as we did not observe increased 
occupancy of the Pdx1 promoter by FoxO1 when HCF-1 is depleted, mammalian 
HCF-1 likely modulates Pdx1 expression through a FoxO1-independent mechanism.  
Future studies examining global FoxO chromatin localization in the absence of HCF-1 
will be critical for determining which specific subset of FoxO target genes may be co-
repressed by HCF-1.  
A well-established role of HCF-1 is to promote E2F1-mediated transcription to 
affect cell proliferation (Tyagi et al., 2007).  Recent studies have highlighted a role for 
E2F1 in pancreatic β-cell function in vivo.  E2F1 null mice have reduced expression of 
Pdx1, reduced pancreatic β-cell mass and reduced pancreatic insulin content (Fajas et 
al., 2004).  E2F1 also regulates insulin secretion through promoting the expression of 
the KATP channel, Kir6.2, involved in glucose-stimulated insulin secretion (Annicotte 
et al., 2009).  Our data suggest HCF-1 likely modulates pancreatic β-cell function by 
regulating the expression of multiple critical E2F1 target genes involved in distinct 
aspects of β-cell function.  Future global analysis to identify the transcriptional targets 
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commonly regulated by HCF-1 and E2F1 will reveal the key downstream mediators 
likely contributing to the common phenotypes observed in HCF-1- and E2F1-deficient 
β-cells.    
In conclusion, we have identified a role for transcriptional co-regulator HCF-1 
as an essential regulator of Pdx1 expression, with consequences to β-cell growth, 
survival and glucose-stimulated insulin secretion.  Thus, HCF-1 represents a novel 
target for future therapies aimed at treating and preventing the progression of diabetes.   
 
3.5 MATERIALS AND METHODS 
3.5.1 Cell culture, siRNA transfection and immunoblotting 
INS-1 cells were maintained and transfected with siRNA as previously 
described, with some modifications (Rizki et al., 2011).  In brief, INS-1 cells were 
transfected twice, one day apart, with 5nM siRNA using Lipofectamine RNAiMax per 
the manufacturer’s protocol.  siRNA duplexes directed against rat HCF-1 were 
purchased from Dharmacon and targeted the following sequences: ; siHCF-1 #1: 5’-
AGAACAACATTCCGAGGTA-3’; siHCF-1 #2: 5’-GCTTATAAATTTCGAGTTG-
3; siHCF-1 #3 5’-CGGCAAGATTATCGAGTAC-3’; siHCF-1 #4:  5’-
GGAAGAGACTGAAGGCAAA-3’.  Non-targeting control siRNA was also from 
Dharmacon.  Preparation of cell lysates and immunoblotting were performed as 
described previously (Rizki et al., 2011).  The following antibodies were used:  HCF-1 
(Bethyl Labs), β-actin (Millipore), Pdx1, total caspase-3, cleaved caspase-3, FoxO1 
(Cell signaling), E2F1 (Santa Cruz) and HA (Covance).       
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3.5.2 Cell growth curve and caspase-3 cleavage analysis 
10
5
 cells were seeded in each well of a 6-well plate at the time of the first 
siRNA transfection.  3 wells per condition were counted using the trypan blue 
exclusion method.  Cells were lysed and western blot analysis was done using total 
caspase-3 and cleaved caspase-3 antibody.     
 
3.5.3 BrdU incorporation assay 
10
5
 cells were seeded in each well of a 6-well plate containing a glass coverslip 
at the time of the first siRNA transfection.  Three days after the first siRNA 
transfection, cells were incubated in media containing 10 µM BrdU (Sigma).  The 
following day, cells were fixed and stained with anti-HCF-1 and anti-BrdU antibody 
(Julien and Herr, 2003).  Cells were fixed in 2% paraformaldehyde, permeabilized 
with 0.5% TritonX-100, and blocked for 20 minutes in 3% BSA.  Coverslips were 
incubated with anti-HCF-1 antibody (Bethyl Labs) for 1 hour, washed and incubated 
with cy3-conjugated anti-rabbit IgG for 30 minutes, fixed and DNA denatured with 
4N HCl for 20 minutes, and incubated with FITC-conjugated anti-BrdU (BD 
Biosciences) antibody.  Nuclei were stained with DAPI.  Coverslips were mounted on 
glass slides using Vectashield (Vector Labs).  Coverslips were examined and pictures 
obtained on a Leica DM 5000B fluorescent microscope.  At least 400 cells were 
counted per siRNA treatment.   
 
3.5.4 Reverse-transcription coupled quantitative PCR (RT-qPCR): 
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RNA was isolated from INS-1 cells treated with the indicated siRNAs using 
Trizol reagent and was reverse-transcribed using Superscript III First-Strand kit 
(Invitrogen).  cDNAs were analyzed by quantitative-PCR using the SYBR Green 
system on a Roche LightCycler 480 real time PCR machine and quantified relative to 
a standard curve.  β-actin was used as an internal control.  Primer sequences can be 
found in Table 3.1. 
 
3.5.5 Glucose-stimulated insulin secretion and intracellular insulin content 
analysis 
10
6
 INS-1 cells were sequentially transfected with sicontrol or HCF-1 siRNA 
in 10 cm plates.  One day after the second siRNA transfection, cells were trypsinized 
and seeded at 10
6
 cells per well in 24-well plates in RPMI medium containing 5mM 
glucose.  The following day, cells were washed once with warm KRB buffer (119mM 
NaCl, 4.74mM KCl, 2.54mM Ca Cl2, 1.19mM MgSO4, 1.19mM KH2PO4, 25mM 
NaHCO, 10mM HEPES and 0.2% fatty acid free BSA) and incubated for one hour in 
0.5mL KRB buffer at 37°C.  Cells were then incubated in 0.5mL of KRB buffer 
containing either 3mM or 16.7mM glucose for 1 hour at at 37°C.  Supernatant was 
collected and insulin measured using a rat/mouse insulin ELISA kit (Millipore).  Cells 
were lysed in cell lysis buffer or incubated with acifidied ethanol (75% ethanol, 1.5% 
HCl) overnight at -20°C to measure intracellular insulin content.  Insulin 
measurements were normalized to cellular protein content as determined by Bradford 
assay.    In the case of HCF-1 overexpression, cells with stable integration of 
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pInducer20-HA-HCF1 were treated with 200ng/ml doxycycline for 24 hours before 
being subjected to the glucose-stimulated insulin secretion assay. 
 
3.5.6 Co-Immunoprecipitation Assay  
INS-1 cells were infected and selected for stable integration of pInducer20-
HA-HCF1, as previously described (Meerbrey et al., 2011).  Stable cells were treated 
with 1ug/ml of doxycycline for 24 hours to induce expression of HA-HCF1.  Cells 
were collected, and lysed in buffer containing 50mM Tris-HCl pH 8.0, 100mM NaCl, 
2mM EDTA, 1% TritonX-100, 10mM NaF, 1mM sodium orthovanadate, 1mM 
PMSF, 10mM nicotinamide, 1mM trichostatin A, and protease inhibitors.  Cell 
extracts were incubated HA-conjugated agarose beads (Sigma) overnight at 4°C.  
Beads were washed five times in lysis buffer and eluted with HA-peptide (Sigma).   
Immunoprecipitates were analyzed by western blotting using the following antibodies: 
anti-HA (Covance), anti-FoxO1 (Cell Signaling), anti-E2F1 (Santa Cruz).   
 
3.5.7 Chromatin Immunoprecipitation (ChIP) Assays 
1.5 x 10
6
 INS-1 cells were transfected with siRNA in 10cm plates as described 
above.  Two days after the second siRNA transfection, cells were cross-linked with 
1% formaldehyde for 10 minutes at room temperature.  Glycine was added to a final 
concentration of 125mM for 5 minutes.  Cells were washed with cold PBS and lysed 
in buffer containing 25mM HEPES, 1.5mM MgCl2, 10mM KCl, 0.5% NP40, 1mM 
DTT and protease inhibitors.  Nuclei were pelleted and lysed in buffer containing 
50mM HEPES, 140mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% sodium 
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deoxycholate, and protease inhibitors, and sonicated using a Diogenode Bioruptor.  
Chromatin was immunoprecipitated overnight using antibodies against HCF-1 (Bethyl 
labs A301-399A), E2F1 (Santa Cruz, C-20) or FoxO1 (Santa Cruz, H-128) and 
recovered with protein A agarose resin (Thermo Scientific).  The protein A resin was 
washed, immunoprecipitated complexes eluted, and crosslinks reversed.  DNA was 
purified using Qiagen PCR purification kit, and assayed by quantitative PCR.  Primer 
sequences can be found in Table 3.1. 
 
3.5.8 Data Analysis 
Data are represented as mean +/- SEM and analyzed by the Student’s t-test, 
except for the BrdU incorporation assay, which is represented as mean and 95% 
confidence interval and analyzed by Chi-squared test.  A p-value of less than 0.05 was 
considered to be statistically significant. 
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CHAPTER 4 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The utility of genetic model organisms in helping to demystify complex 
biological phenomena is clear.  As a result of experiments done in a simple 
roundworm, our understanding of the aging process has broadened tremendously.  The 
discoveries made in C. elegans are extremely relevant to humans as we observe highly 
conserved mechanisms of longevity determination between worms and mammals.  
Most importantly, these findings have promoted the development of therapeutics 
aimed at preventing or delaying the onset of age-related diseases in people (Yang and 
Hung, 2009; Blum et al., 2011).  My research, which stems from the finding that HCF-
1 acts in C. elegans longevity determination, shows that mammalian HCF-1 plays 
critical roles in regulating cellular proliferation, surivival and metabolism and is 
involved in a regulatory network involving the sirtuin SIRT1 and the FoxO 
transcription factors.  These interactions are highly conserved between C. elegans and 
mammals (Rizki et al., 2011), again highlighting the importance of HCF-1 as an 
evolutionarily conserved modulator of putative longevity determinants.   
Many studies have focused on the various cytosolic signaling pathways that 
respond to extracellular signals and converge on FoxO to modulate cellular responses.  
However, relatively few studies have examined in depth the nuclear regulation of 
FoxO transcriptional activity.  My results are the first to implicate mammalian HCF 
proteins as conserved nuclear co-repressors of FoxO, with consequences to FoxO 
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target genes involved in apoptosis, cell cycle arrest and metabolism.  These findings 
point to a novel nuclear FoxO/HCF-1 regulatory complex responsible for determining 
cellular fates, with direct implications to mammalian cancer biology, metabolism and 
aging. 
By identifying HCF-1 as a novel target of sirtuin-mediated deacetylation, I 
have also shed light on a novel actor likely to be integral in mediating sirtuin-
dependent cellular processes, particularly those sensitive to energy availability.  Given 
their dependence on cellular NAD
+ 
levels, sirtuins are sensitive to cellular redox status 
and energy status.  NAD
+
 acts as a co-factor for glycolytic redox reactions, the Krebs 
cycle, the catabolism of macromolecules, as well as a number of other cellular 
processes.  Thus the pool of NAD
+
 available for sirtuin-mediated enzymatic reactions 
is limited (Imai and Guarente, 2010).   NAD
+
 biosynthesis involves the enzyme 
nicotinamide phosphoribosyltransferase (NAMPT), which is regulated by ATP levels 
through AMP-kinase.  Thus, under low energy conditions, AMPK activation leads to 
increased NAD
+
 levels and increased SIRT1 activity (Imai and Guarente, 2010), 
mirroring the effect of AMPK on FoxO activation, reviewed in Chapter 1.  The likely 
outcome of SIRT1 activation under low energy conditions would be increased HCF-1 
deacetylation.  My results suggest, then, that SIRT1 deacetylation of HCF-1 may lead 
to inactivation of HCF-1, further enhancing FoxO activity under low energy states.   
Furthermore, the effect of SIRT1-mediated deacetylation of HCF-1 may 
extend to other processes regulated by HCF-1, independent of FoxO.  As HCF-1 is 
known to be involved in cell proliferation, it is tempting to think that HCF-1 may act 
as a nutrient sensor, linking cellular energy levels to cellular proliferation.  Under low 
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energy states, HCF-1 may be inhibited by SIRT1-mediated deacetylation.  Conversely, 
as glucose stimulates the production of ATP, elevated glucose concentrations would 
inhibit SIRT1-mediated deacetylation of HCF-1, resulting in more acetylated HCF-1, 
which might then act to promote the transcription of genes involved in cell growth. In 
support of this hypothesis, I observe that increasing concentrations of glucose 
increases HCF-1 acetylation (Figure AIII).  Future studies directly assessing the role 
that acetylation plays in modulating HCF-1 activity will be critical to further our 
understanding of how HCF-1 regulates key cellular processes. 
My analyses have identified not only that sirtuins promote deacetylation of 
HCF-1, but that they do so by targeting lysines found within the basic region of HCF-
1.  Interestingly, HCF-1 proteolysis is regulated by the glucose-sensitive O-linked-β-
N-acetylglucosaminyl transferase (OGT) protein (Capotosti et al., 2011; Daou et al., 
2011).  OGT modifies HCF-1 by the addition of O-GlcNac moieties on residues 
located in and around the basic region (Wang et al., 2007b; Capotosti et al., 2011).  
Given that post-translational modifications may interact to direct the functional 
activity of target proteins, it is possible that O-GlcNacylation and deacetylation of 
HCF-1 crosstalk to regulate HCF-1 proteolysis and activity.  Future studies will help 
elucidate how post-translational modifications of HCF-1 may alter HCF-1 function in 
response to specific environmental signals. 
 In the context of pancreatic β-cells, my work is the first to show that HCF-1 is 
required for β-cell proliferation, survival and glucose-stimulated insulin secretion.  I 
have found that HCF-1, likely in cooperation with E2F1, promotes the expression of 
Pdx1, a critical transcription factor with major roles in pancreatic β-cell 
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differentiation, growth, survival, insulin synthesis and glucose-stimulated insulin 
secretion.  These findings clearly implicate HCF-1 as a novel factor involved in 
maintenance of pancreatic β-cell function with direct implications to diabetes 
development and progression. 
As discussed, HCF-1 may be critically involved in responding to energy 
availability by promoting cell survival and cell growth.  Given the dependence of 
insulin secretion on glucose concentrations, and given the likely role that HCF-1 plays 
in responding to cellular energy levels through SIRT1-mediated deacetylation, this 
leads to the intriguing possibility that SIRT1 interactions with HCF-1 may alter 
glucose-mediated insulin secretion from pancreatic β-cells.  SIRT1 is already known 
to be involved in pancreatic insulin secretion (Moynihan et al., 2005; Bordone et al., 
2006), suggesting that SIRT1 and HCF-1 may interact to affect pancreatic β-cell 
function as well.  Future studies looking directly at HCF-1 acetylation in the context of 
insulin secretion will thus be of great interest.  So too will studies examining the in 
vivo consequences of altered HCF-1 activity on pancreatic β-cell function. 
In addition to a role in pancreatic β-cells, my preliminary experiments in pre-
adipocytes and mouse embryonic stem cell lines, discussed in Appendix I and 
Appendix II, suggest that HCF-1 and HCF-2 play important roles in these cell types as 
well.  A more extensive analysis of cells, and possibly mice, with altered activities of 
HCF-1 and HCF-2 will provide valuable insight into the cell- and tissue-specific 
functions of these factors. 
Ultimately, as IIS and FoxO factors are believed to affect longevity in 
mammals, it will be of great interest to perform lifespan analyses with mice in which 
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HCF levels have been altered.  Given that HCF-1 is critical for promoting cell cycle 
proliferation and glucose stimulated insulin secretion in cell culture systems, it is 
likely that whole body ablation of HCF-1 will result in non-viable and/or diabetic 
animals that are unlikely to live prolonged lives.  However, in mammals as well as in 
invertebrates, the IIS pathway and FoxO transcription factors appear to act in specific 
tissues, most notably adipose and neuronal tissues, to confer lifespan extension 
(Bluher et al., 2003; Libina et al., 2003; Giannakou et al., 2004; Broughton et al., 
2005; Taguchi et al., 2007).  This suggests, then, that altering HCF-1 function in brain 
and adipose tissue alone may be sufficient to promote longevity.   
 In conclusion, my studies are the first to a) establish a role for HCF-1 in 
repressing mammalian FoxO activity, b) identify HCF-1 as a novel target deacetylated 
by sirtuins, and c) provide evidence for HCF-1’s essential role in regulating pancreatic 
β-cell function and glucose homeostasis. With the development of additional reagents 
to study the in vitro and in vivo functions of mammalian HCF-1, we will be able to 
dissect in detail the molecular mechanisms that govern the activity of this essential 
transcriptional regulator, and gain insight into possible methods of targeting HCF-1 to 
prevent metabolic and age-associated diseases, and to prolong healthy lives. 
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APPENDIX I 
 
INVESTIGATING THE ROLE OF HCF-1 AND HCF-2 IN ADIPOCYTE 
DIFFERENTIATION 
 
In addition to roles in pancreatic β-cells, FoxO1 also regulates the 
differentiation of adipocytes (Nakae et al., 2003).  As we have shown that mammalian 
HCF-1 and HCF-2 functionally and physically interact with FoxO proteins (Rizki et 
al., 2011), we sought to determine whether HCF-1 may also be involved in the 
regulation of adipocyte differentiation.   
During adipogenesis, a cascade of transcriptional activation mediated by the 
transcription factors peroxisome proliferator-activated receptor gamma (PPARγ) and 
CCAAT/enhancer-binding proteins (C/EBPs) leads to the differentiation of fibroblast-
like preadipocytes into lipid-filled adipocytes (Lefterova and Lazar, 2009).  An early 
increase in the expression of C/EBPβ and C/EBPδ during adiopcyte differentiation 
drives the induction of PPARγ and C/EBPα (Cristancho and Lazar, 2011).  PPARγ 
expression is further upregulated by auto-regulation of its own promoter, and through 
continued transcriptional activation by C/EBPα and C/EBPδ (Cristancho and Lazar, 
2011).  FoxO1 inhibits adipocyte differentiation by repressing the transcription of the 
PPARγ gene (Armoni et al., 2006), as well as by inhibiting the transcriptional activity 
of PPARγ itself (Dowell et al., 2003; Fan et al., 2009).  Expression of constitutively 
active FoxO1 prevents adipogenesis (Nakae et al., 2003), whereas haploinsufficiency 
of FoxO1 results in increased adipose PPARγ activity (Kim et al., 2009).  We 
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hypothesized that HCF proteins repress FoxO1 in adipocytes, thereby acting to 
promote adipogenesis. 
To determine whether HCF proteins are involved in regulating adipocyte 
differentiation, we utilized the 3T3-L1 cell model of adipogenesis (Green and 
Kehinde, 1975).  During adipocyte differentiation, we observe upregulation of both 
HCF-1 and HCF-2 expression (Figure AI.1).  Using retroviral-mediated shRNA to 
knockdown HCF-1 or HCF-2, we found that reducing HCF-1 resulted in decreased 
expression of PPARγ (Figure AI.2A), whereas HCF-2 knockdown results in increased 
PPARγ expression (Figure AI.2A).  These observations suggest that HCF-1 may 
indeed play a role in repressing FoxO1 as reducing HCF-1 expression may lead to 
increased activation of FoxO1 and subsequent downregulation of the FoxO1 target, 
PPARγ.  In contrast, HCF-2 knockdown results in upregulation of PPARγ, suggesting 
that HCF-1 and HCF-2 play divergent roles in adipocytes.  Future analysis of HCF-1 
and HCF-2 in adipocytes will help to better define the role of HCF proteins in 
adipogenesis.  
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Figure AI.1 HCF-1 and HCF-2 expression is upregulated during adipogenesis.  
3T3-L1 preadipocytes were induced to differentiate with a cocktail of 3-isobutyl-1-
methylxanthine, dexamethasone and insulin on day 0.  mRNA levels of HCF-1 (A) 
and HCF-2 (B) were analyzed at the indicated timepoints. Values are normalized to 
the level of the ribosomal protein transcript, L32.  The mean normalized mRNA level 
for each gene at day 0 was set to 1.  The data represented are pooled from three 
independent experiments.   
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Figure AI.2  HCF-1 and HCF-2 regulate expression of the FoxO1 target gene, 
  PPARγ, in a divergent manner. 
3T3-L1 preadipocytes were infected with retroviral shRNA vectors targeting the 
luciferase, Xbp1, HCF-1 or HCF-2 genes.  shLuc served as a negative control, while 
shXbp1 served as a positive control for reduced PPARγ gene expression (Sha et al., 
2009).  (A) mRNA levels of  PPARγ over the course of adipocyte differentiation. (B) 
mRNA levels of HCF-1 and HCF-2 in the indicated cell lines.  Values are normalized 
to the level of the ribosomal protein transcript, L32.  The mean normalized mRNA 
level for each gene at day 0 was set to 1. Experiment was conducted at least three 
times with similar results.  Data shown are from one representative experiment.   
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APPENDIX II 
 
EXAMINATION OF HCF-1 AND HCF-2 IN MOUSE EMBRYONIC STEM 
CELLS  
 
Recent studies in mammalian systems suggest that aging is influenced by stem 
cells, and the functional decline in stem cells with age can contribute to pathological 
disease conditions (Sharpless and DePinho, 2007; Rossi et al., 2008).  For instance, 
hematopoietic stem cells (HSCs), the best-characterized of adult stem cells, are known 
to undergo age-dependent changes.  A decline in HSC function leads to disease 
conditions that manifest in older individuals, such as immunodeficiency, neoplasia, 
and anemia (Sharpless and DePinho, 2007).  Other stem cell compartments are 
similarly affected by aging.  One hypothesis for this decline in stem cell function is 
that reactive oxygen species (ROS)-induced damage can impair stem cell self-renewal 
(Rossi et al., 2008).  Support for this theory comes from studies indicating that FoxO 
proteins function to maintain the hematopoietic stem cell, as well as the neural stem 
cell pool by affecting ROS levels (Miyamoto et al., 2007; Tothova et al., 2007; Paik et 
al., 2009).   A conditional FoxO1/3/4-null mouse model exhibited defects in HSC 
quiescence and self-renewal, and increased levels of endogenous ROS (Tothova et al., 
2007).  Mice with a homozygous deletion of the FoxO3 gene also showed elevated 
ROS levels in HSC, and defects in the maintenance of the quiescent state (Miyamoto 
et al., 2007).  In neural stem cells, combined loss of FoxO1, FoxO3 and FoxO4 
resulted in increased ROS levels, decreased cell proliferation, and hence a reduced 
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neural stem cell pool (Paik et al., 2009).  SIRT1 has also been implicated to be 
essential for hematopoietic stem cell differentiation (Ou et al., 2011; Matsui et al., 
2012) suggesting that HCF-1, which interacts with both FoxO and SIRT1, may also be 
involved in maintaining adult stem cell function.   
In addition, both FoxO and SIRT1 play critical roles in embryonic stem cells 
(ESCs).  ESCs exhibit the key properties of self-renewal capacity and the potential to 
differentiate into any cell type in the body.  Thus, pluripotent ESCs are an attractive 
potential agent for the treatment of age-dependent diseases.  FoxO1 functions to 
maintain pluripotency of human and mouse embryonic stem cells by promoting the 
expression of the pluripotency factors OCT4 and SOX2 (Zhang et al., 2011b).  Recent 
studies indicate that SIRT1 is a regulator of ESC differentiation and responses to 
oxidative stress.  SIRT1, in contrast to FoxO1, regulates p53 activity in ESC to inhibit 
differentiation and induce apoptosis under increased ROS conditions (Han et al., 
2008).  These studies imply that factors involved in lifespan modulation also play a 
role in both adult and embryonic stem cell function.  Given the importance of stem 
cell function in tissue homeostasis and implications for therapies targeting stem cells, 
identification of additional factors involved in stem cell maintenance is of great 
interest.   
Recently, HCF-1 has also been implicated in ESC regulation through a novel 
stem cell factor, Ronin.  Ronin is required to maintain ESC pluripotency, and Ronin 
associates with HCF-1 and other chromatin modifiers in ESCs (Dejosez et al., 2008).  
Furthermore, HCF-1 and Ronin occupy the promoters of many shared genes in ESCs 
(Dejosez et al., 2010).  Precisely how Ronin interacts with HCF-1 to affect 
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pluripotency of ESCs is still unclear.  HCF-1 is well-known to be critical for the 
progression of multiple phases of the cell cycle (Julien and Herr, 2003, 2004; Tyagi et 
al., 2007).  HCF-1 can also recruit chromatin modifiers to target gene promoters of 
specific E2F transcription factors that regulate cell cycle progression (Tyagi et al., 
2007).  E2F1 is also associated with increased expression of genes specifically 
upregulated in pluripotent embryonic stem cells, and is important for maintaining the 
rapid cell cycling of ESCs (Stead et al., 2002; Chen et al., 2008b).  Thus, HCF-1 may 
be involved in regulating ESC function through interactions with FoxO1, SIRT1 
and/or E2F1. 
To assess whether HCF-1 proteins may be involved in regulating ESC 
pluripotency and self-renewal, we first analyzed the expression of HCF-1 and HCF-2 
in ESCs during differentiation.  Mouse ESCs can be maintained in a pluripotent and 
self-renewing state when grown in culture media containing the cytokine leukemia 
inhibitory factor (LIF).  Removal of LIF, and/or treatment with retinoic acid, promotes 
differentiation of mouse ESCs.  Consistent with a role for HCF-1 in regulating ESC 
self-renewal and differentiation I find that HCF-1 is expressed in undifferentiatied 
ESCs, and expression of HCF-1 is reduced during retinoic-acid and LIF-withdrawal 
induced differentiation (Figure AII.1A-B).  In contrast, HCF-2 mRNA levels appear 
relatively stable over the differentiation time course (Figure AII.1C).  This suggests 
that HCF-1 plays an important role in undifferentiated ESCs, and that loss of HCF-1 
expression may promote differentiation of ESCs.   
We next analyzed the phenotype of mouse ESCs in which expression of HCF-
1 or HCF-2 was reduced.  We electroporated mouse ESCs with plasmids encoding 
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shRNA targeting either HCF-1 or HCF-2, and selected for stable expression of the 
shRNA.  We then induced differentiation of the ESCs by removing leukemia 
inhibitory factor, and performed RT-qPCR to assess the expression level of various 
pluripotency factors.  HCF-1 expression was reduced about by 50% in shHCF1-
expressing ESCs at the initiation of LIF-withdrawal compared to ESCs expressing a 
negative control shRNA (Fig. AII.2A), whereas HCF-2 expression was reduced by 
about 10-fold throughout the time course of LIF-withdrawal (Fig. AII.2B).  
Interestingly, cells depleted of HCF-2 exhibited reduced levels of the pluripotency 
factors Nanog, Oct4, and Sox2 at two and four days after LIF-withdrawal (Fig. 
AII.2C-E).  In contrast, HCF-1 knockdown cells expressed elevated levels of Nanog, 
but no consistent changes to Oct4 or Sox2 (Fig. AII.2C-E).  To test whether cells with 
reduced HCF-1 or HCF-2 levels were more differentiated than the control cells, we 
measured alkaline phosphatase activity in these ESCs.  Alkaline phosphatase is highly 
expressed in undifferentiated ESCs, and can be used as a marker for the differentiated 
versus undifferentiated state. Despite the changes we see in gene expression, there was 
no significant change in the level of alkaline phosphatase activity in cells expressing 
shRNA against either HCF-1 or HCF-2 as compared to the negative control cells.  
However, we did not measure alkaline phosphatase activity during LIF-withdrawal, 
which likely accounts for this discrepancy as changes in pluripotency genes’ 
expression were not apparent in our HCF-1 and HCF-2 knockdown cell lines until 
differentiation had been initiated.  While these results hint at the possibility that HCF-
1 and HCF-2 may be involved in ESC differentiation, these experiments were 
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peformed only once, necessitating further analysis to determine what, if any, role 
HCF-1 or HCF-2 play in ESC self-renewal and differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 
 
 
 
 
 
 
Figure AII.1 HCF-1 expression is reduced during mouse embryonic stem cell 
  differentiation. 
(A) Western blot of HCF-1 protein levels in mouse embryonic stem cells (mESCs) 
kept in the undifferentiated state with the presence of leukemia inhibitory factor (+ 
LIF), or induced to differentiate by the withdrawal of LIF and the addition of retinoic 
acid, (-LIF, +RA).  (B) mRNA levels of HCF-1 in undifferentiated or differentiating 
mESCs as quantified by RT-qPCR.  (C) mRNA levels of HCF-2 in undifferentiated or 
differentiating mESCs as quantified by RT-qPCR.  Results shown are pooled from 
two independent experiments, and represented as mean +/- SD.   
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 Figure AII.2 HCF-1 and HCF-2 may regulate the expression of 
  ESC pluripotency genes. 
Mouse ESCs were selected for stable expression of shRNA targeting HCF-1 or HCF-
2.  Leukemia inhibitory factor (LIF) was removed from the culture media to induce 
differentiation.  RT-qPCR was used to analyze the level of gene expression on the 
indicated day after LIF withdrawal.  mRNA values for each gene are normalized to the 
level of β-actin, and the mean normalized mRNA level day 0 in shNeg cell lines was  
set to 1.  Results shown are mean +/- SD.  Experiment was performed once. 
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Figure AII.3 Alkaline phosphatase activity in HCF-1 and HCF-2 knockdown 
  ESCs.  
Alkaline phosphatase activity was measured in mouse ESCs selected for stable 
expression of shRNA targeting HCF-1 or HCF-2 using the StemTAG Alkaline 
Phosphatase Activity Assay Kit from Cell Biolabs, Inc.  Values are normalized to total 
protein content, and shown as mean +/- SD.  Experiment was performed once. 
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APPENDIX III 
 
HCF-1 ACETYLATION IS INCREASED UNDER HIGH GLUCOSE 
CONDITIONS 
 
 As a NAD
+
-dependent enzyme, SIRT1 activity is known to be regulated by 
nutrient and energy status (Imai and Guarente, 2010).  NAD
+
 is an essential cofactor 
for glycolytic redox reactions and other cellular metabolic processes, which results in 
a limited pool of NAD
+
 available for sirtuin-mediated enzymatic reactions (Imai and 
Guarente, 2010).   NAD
+
 biosynthesis is regulated by the AMP-activated protein 
kinase (AMPK) (Fulco et al., 2008; Canto et al., 2009).  Under low glucose 
conditions, AMPK activation leads to increased NAD
+
 levels and hence increased 
SIRT1 activity (Fulco et al., 2008).  Therefore, we wondered whether energy 
availability might affect SIRT1-mediated deacetylation of HCF-1.   
 We overexpressed HA-tagged HCF-1 in HEK293T cells, and treated the cells 
with varying glucose concentrations.  HA-HCF-1 was immunoprecipitated from the 
cell lysate and acetylation determined by western blotting.  Interestingly, we observed 
that increasing glucose concentrations result in increased levels of HCF-1 acetylation 
(Figure AIII).  Thus, we conclude that HCF-1 deacetylation by SIRT1 is likely 
sensitive to cellular energy status. 
 Given that HCF-1 is required for glucose-stimulated insulin secretion in INS-1 
β-cells, it is tempting to think that HCF-1 may act as a glucose sensor, and that by 
being acetylated or deacetylated, HCF-1 function may be responsive to cellular energy 
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availability.  Future studies examining the functional consequences of HCF-1 
acetylation will help elucidate how energy status may affect HCF-1-dependent cellular 
processes. 
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Figure AIII HCF-1 acetylation is sensitive to glucose concentrations. 
(A) HA-tagged HCF-1 was immunoprecipitated from cells treated with the indicated 
glucose concentrations for 6 hours.  Acetylated HCF-1 was detected using a pan-
acetyllysine antibody.  Whole cell lysate was subjected to immunoblotting for SIRT1 
and β-actin.  (B) Ac-HCF1 levels were normalized to total HA-HCF-1 levels and 
quantified using a Biorad ChemiDoc imaging system.  The normalized level of Ac-
HCF1 was set to 1 in the 5.5mM glucose condition.   
 
 
 
 
 
 
 
 
 
 
 108 
 
 
 
 
 
 
 109 
APPENDIX IV 
 
MAMMALIAN HCF-2 IS UPREGULATED BY SERUM STARVATION BUT 
IS NOT REQUIRED FOR CELL CYCLE ARREST OR PROGRESSION 
 
 Given that HCF-1 is required for multiple aspects of cell cycle progression 
(Goto et al., 1997; Wilson et al., 1997; Julien and Herr, 2003, 2004), we were curious 
to test whether the closely related HCF-2 protein might be involved in cell cycle 
regulation as well.  We have observed that mouse NIH3T3 fibroblast cells treated with 
serum depletion and the PI3-kinase inhibitor LY294002 exhibit elevated levels of 
HCF-2 mRNA transcripts (Figure AIV.1A).  LY294002 treatment alone induces HCF-
2 expression by about 50% (Figure AIV.1A) while serum starvation alone was able to 
induce HCF-2 expression ~3-fold. (Figure AIV.1A).  The combination of serum 
depletion and LY294002 treatment is additive, suggesting that these are two 
independent pathways mediating HCF-2 upregulation.  We then tested whether HCF-2 
upregulation is a general stress response by examining HCF-2 mRNA levels after 
oxidative stress (H2O2) or UV treatment (Figure AIV.1B-C).  However, UV treatment 
only mildly induced HCF-2 expression (~15% after 12 hours), while H2O2 reduced 
HCF-2 expression, indicating that serum depletion specifically promotes the robust 
upregulation of HCF-2. 
As serum depletion promotes G1 cell cycle arrest (Pardee, 1974; Campisi et 
al., 1984), we wondered whether HCF-2 might be involved in either promoting cell 
cycle arrest or in reiniating the cell cycle after serum stimulation.  To test this, we 
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generated stable NIH3T3 cell lines in which shRNA targeting the HCF-2 gene was 
constitutively expressed.  HCF-2 transcripts were reduced by ~70% in the cells 
expressing the HCF-2 shRNA relative to control cells expressing shRNA targeting the 
luciferase gene (Figure AIV.2A).  We then subjected these cells to serum depletion 
(0.5% calf serum) and assessed their DNA content by propidium iodide staining and 
flow cytometry analysis.  The shLuc and shHCF2 cells behaved similarly, with both 
cell lines exhibiting progressively increased percentage of cells with G1 DNA content 
(Figure AIV.2B).  This result suggests that HCF-2 is not required for cell cycle arrest 
in response to serum deprivation.  We next assessed whether cells depleted of HCF-2 
exhibited any defects in re-entering the cell cycle after being arrested by serum 
depletion. Cells growing in serum-containing culture media (“+Serum”, 10% calf 
serum) were first subjected to serum deprivation (0.5% calf serum) for 48 hours (“-
Serum 48h”) to induce G1 arrest (Figure AIV.2C).  Media containing 10% calf serum 
was then added back to the cells and cells were collected at the indicated timepoints.  
Flow cytometric analysis of cellular DNA content again revealed that after 48 hours of 
serum deprivation, cells were predominantly in the G1 phase of the cell cycle.  After 
serum stimulation, both the shLuc and shHCF2 cell lines were able to re-enter the cell 
cycle, as seen by the increase in G2/M-phase and S-phase cell populations (Figure 
AIV.2C).  These results indicate that reducing HCF-2 expression does not impair the 
ability of cells to either exit or re-enter the cell cycle.  One caveat of these experiments 
is that although we have reduced expression of HCF-2 in our stable cell lines, there 
may still be sufficient HCF-2 protein remaining in these cells to carry out the protein’s 
cellular functions.  In addition, as there are no commercial antibodies available that 
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can detect endogenous HCF-2 protein, we are unable to assess the extent of HCF-2 
protein reduction in our shHCF2 cell lines.  Future studies utilizing HCF-2 knockout 
cells will be useful in determining whether HCF-2 plays a role in regulating cell cycle 
events. 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 112 
 
 
 
 
 
 
Figure AIV.1 HCF-2 is upregulated by serum starvation, but not by UV or  
  oxidative stress. 
(A) NIH3T3 cells were treated with vehicle, serum starvation (“SS”), 20µM 
LY294002 (“LY”), or a combination of serum starvation and LY294002.  Cells were 
collected after 12 hours.  (B) NIH3T3 cells were irradiated with 20J/m
2
 of UV-C light.  
Cells were collected at the indicated timepoints after exposure.  (C) NIH3T3 cells 
were treated with 1mM H2O2 for the indicated number of hours.  HCF-2 transcripts 
were measured by RT-qPCR, and normalized to the level of β-actin.  All results are 
from one representative experiment and are shown as mean +/- S.D.   
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Figure AIV.2 HCF-2 is not required for cell cycle arrest or cell cycle progression 
(A) HCF-2 mRNA levels in NIH3T3 cells stably expression shRNA targeting the 
control luciferase gene (shLuc) or the HCF-2 gene (shHCF2).  (B) Stable shRNA cell 
lines were subjected to serum deprivation (0.5% calf serum) for the indicated time 
points.  Percentage of cells in each phase of the cell cycle was determined by 
propidium iodide staining and flow cytometry.  Data were analyzed with FlowJo 
software.  Experiment was performed once.  (C) Stable shRNA cell lines were 
subjected to serum deprivation (0.5% calf serum) for 48 hours and then re-stimulated 
with 10% calf serum.  Cells were collected before and after serum deprivation, and at 
the indicated time points after re-stimulation with 10% calf serum.  DNA content was 
analyzed as in (B).  Experiment was performed once. 
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APPENDIX V 
 
C. ELEGANS HCF-1 MODULATES LIFESPAN UPSTREAM OF HSF-1 AND 
SMK-1, AND IN PARALLEL TO THE GERMLINE SIGNALING PATHWAY
3
  
 
While C. elegans DAF-16 represents a major downstream target of HCF-1 in 
longevity determination, we wondered if other pathways and nuclear factors may also 
interact with HCF-1 to modulate lifespan.  In parallel to the insulin/IGF-1 signaling 
pathway, signals originating in the C. elegans germline converge on DAF-16 to affect 
lifespan (Hsin and Kenyon, 1999).  Worms in which the germline precursor cells are 
ablated (Hsin and Kenyon, 1999), or in which genetic manipulation prevents germ cell 
proliferation (Arantes-Oliveira et al., 2002) exhibit a robust extension of lifespan, 
which is dependent on daf-16. Germline defective mutant worms also require kri-1, 
which encodes an ankyrin repeat protein, to exhibit lifespan extension (Berman and 
Kenyon, 2006).   
   In addition to daf-16, a number of other nuclear factors are known to impact C. 
elegans longevity.  HSF-1 is the C. elegans homolog of heat shock factor (HSF) 
protein, a transcription factor responsible for promoting cellular stress resistance.  In 
addition to transcriptional upregulation of chaperone proteins in response to 
proteotoxic stress, HSF-1 is an essential regulator of developmental processes  
(Akerfelt et al., 2010).  Furthermore, HSF-1 also plays an important role in longevity 
                                                 
3
 The analysis of glp-1 (e2141);hcf-1(pk924) lifespan was published in Li J., Ebata A., Dong Y., Rizki, 
G. Iwata T., and Lee SS, PLoS Biology (2008).  The lifespan analysis of smk-1 and hsf-1 RNAi treated 
hcf-1(pk924) mutant worms have also been performed by Ji Li (smk-1), Gizem Rizki (smk-1) and Elliot 
Kahen (smk-1 and hsf-1) with similar results. 
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determination.  In C. elegans, inactivation of hsf-1 shortens lifespan, whereas 
overexpression of hsf-1 results in exended lifespan and increased stress resistance 
(Garigan et al., 2002; Hsu et al., 2003).  Interestingly, depletion of hsf-1 shortens the 
prolonged lifespan of IIS mutant worms, but not that of daf-16 mutant worms, while 
overexpression of hsf-1 requires daf-16 to significantly extend lifespan (Hsu et al., 
2003; Morley and Morimoto, 2004).  These results, along with the finding that DAF-
16 and HSF-1 regulate a shared subset of target genes (Hsu et al., 2003), indicate that 
DAF-16 and HSF-1 work cooperatively to promote longevity and proteotoxic stress 
resistance.   
C. elegans SMK-1 encodes the worm homolog of suppressor of MEK null 
(SMEK), first identified in Dictyostelium as a downstream component of the mitogen 
activpated protein kinase pathway (Mendoza et al., 2005).  SMK-1 acts as a co-
activator of DAF-16 and affects longevity, immune, UV, and oxidative stress 
responses of C. elegans (Wolff et al., 2006).   
To determine whether HCF-1 may influence longevity through interactions 
with the germline signaling pathway, SMK-1 or HSF-1, we performed genetic 
epistasis analysis.  Our results show that HCF-1 acts in parallel to the germline 
signaling pathway to affect lifespan.  In contrast, we find that hsf-1 and smk-1 are both 
required for the lifespan extension phenotype of hcf-1 mutant worms.   These results 
suggest that HCF-1 affects longevity of C. elegans through interactions with multiple 
nuclear factors.   
 
RESULTS 
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hcf-1 acts in parallel to the germline signaling pathway, but upstream of kri-1, to 
modulate lifespan. 
 hcf-1 mutant worms exhibit reduced brood size and increased embryonic 
lethality (Lee et al., 2007; Li et al., 2008a).  As germline proliferation defects are 
known to promote longevity, we tested whether the extended lifespan of hcf-1 mutant 
worms could be related to their brood size phenotype.  To do this, we tested the 
epistatic relationship between hcf-1 mutant worms, and worms lacking functional glp-
1 or kri-1.  glp-1 encodes a LIN-12/Notch family receptor that  is required for 
germline proliferation, and, when inactivated, leads to significant daf-16-dependent 
lifespan extension (Arantes-Oliveira et al., 2002).  kri-1 encodes the homolog of 
human KRIT1, an ankyrin repeat protein which is required for glp-1 mutant lifespan 
extension (Berman and Kenyon, 2006).  We generated double mutant worms 
harboring a putative null mutation of hcf-1 and a temperature-sensitive mutation of 
glp-1.  At the non-permissive temperature, glp-1(e2141) worms lack a germline and 
are long-lived (Arantes-Oliveira et al., 2002).  We reasoned that if hcf-1 mutation 
extends lifespan through effects on germline proliferation, worms lacking both hcf-1 
and glp-1 will not exhibit any further increase in lifespan extension beyond that of the 
single mutant worms.  In fact, we found that the double mutant worms did indeed live 
significantly longer than either the single glp-1 or hcf-1 mutant worms (Figure 
AV.1A), indicating that hcf-1 affects C. elegans lifespan independently of its effects 
on brood size.  Interestingly, however, we did find that mutation or knockdown of kri-
1 in the hcf-1 mutant background did suppress the lifespan extension phenotype of hcf-
1 mutant worms, suggesting that hcf-1 acts upstream of kri-1 in lifespan modulation.  
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kri-1 is required for the lifespan extending effects of the glp-1 mutation (Berman and 
Kenyon, 2006) (Figure AV.IB) and for DAF-16 nuclear localization seen in glp-1, but 
not IIS, mutant worms (Berman and Kenyon, 2006).  kri-1 and also mediates the 
upregulation of lipid hydrolysis seen in both glp-1 and IIS mutant worms (Wang et al., 
2008a).  hcf-1 mutation does not affect DAF-16 nuclear localization (Li et al., 2008a), 
but does affect lipid and fatty acid metabolism (Rizki et al., 2011).  Therefore, it is 
possible that kri-1 mediates the lipid metabolism effects of hcf-1 inactivation.  Future 
analysis of the role that lipid metabolism plays in hcf-1 mutant lifespan will help to 
clarify the importance of altered fat metabolism in promoting longevity. 
  
hsf-1 and smk-1 are both required for hcf-1 mutation to extend lifespan. 
 We next assessed whether hcf-1 interacts with other nuclear factors to affect 
lifespan in C. elegans.  We treated hcf-1 mutant worms with RNAi targeting hsf-1 or 
smk-1 and assessed the effect of the RNAi on worm lifespan.  As a positive control, 
we included daf-16 RNAi, which suppresses the long-lived phenotype of hcf-1 mutant 
worms (Li et al., 2008a) (Figure AV.2A).  We found that knockdown of either hsf-1 or 
smk-1 suppressed the lifespan extension conferred by hcf-1 mutation (Figure AV.2B-
C).  These results indicate that, in addition to DAF-16, HSF-1 and SMK-1 act as 
essential nuclear factors mediating the effects of HCF-1 on C. elegans lifespan.  As 
both HSF-1 and SMK-1 interact with DAF-16 to affect longevity, it will be of great 
interest to determine whether HCF-1 may coordinate the interactions between these 
multiple factors, and by what mechanism it is able to do so. 
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Figure AV.1 hcf-1 acts in parallel to the germline signaling pathway, but  
  upstream of kri-1, to modulate lifespan. 
(A) Lifespans of adult populations of wildtype (wt), hcf-1(pk924), glp-1(e2141), and 
hcf-1(pk924);glp-1(e2141) mutant worms grown at 25°C.  (B) Lifespans of adult 
populations of wt, hcf-1(pk924), glp-1(e2141), kri-1(ok1251) and the indicated double 
mutant worms grown at 25°C.  Each of the lifespan experiments was performed at 
least twice with similar results.  Data from one representative experiment is shown.  
Qualitative data and statistical analysis is included in Table AV.1. 
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Figure AV.2 hsf-1 and smk-1 are both required for hcf-1 mutation to extend 
  lifespan. 
Lifespans of adult populations of wildtype (wt) and hcf-1(pk924) mutant worms 
treated with daf-16 RNAi (A), hsf-1 RNAi (B) or smk-1 RNAi (C).  Data are from one 
experiment. Qualitative data and statistical analysis is included in Table AV.2.  
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Table AV.1 hcf-1 acts in parallel to the germline signaling pathway to modulate 
  lifespan. 
 
 
 
 
 
 
 
 
 
 
Strain
Mean 
survival 
(Days ± 
SEM)
Total 
N
p-value 
vs wt
p-value vs 
hcf-1(pk924) 
% of wt 
lifespan
% of hcf-1 
(pk924) 
lifespan
wildtype 13.57 ± 0.19 56 NA <0.001 NA 77%
hcf-1(pk924) 17.53 ± 0.63 66 <0.001 NA 129% NA
glp-1(e2141) 17.96 ± 0.4 75 <0.001 0.952 132% 102%
kri-1(ok1251) 12.75 ± 0.22 75 <0.05 <0.001 94% 73%
hcf-1(pk924);kri-1(ok1251) 13.39 ± 0.2 70 0.970 <0.001 99% 76%
glp-1(e2141);hcf-1(pk924) 21.4 ± 0.74 62 <0.001 <0.001 157% 122%
glp-1(e2141);kri-1(ok1251) 12.45 ± 0.2 44 <0.001 <0.001 92% 71%
Data are representative of at least two independent experiments.  Statistical analyses were done using SPSS 
software, with Kaplan Meier analysis and log-rank test to determine significance.  p-values <0.05 are 
considered significant. 
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Table AV.2 hcf-1 acts upstream of hsf-1 and smk-1 to modulate lifespan. 
 
 
 
 
 
 
 
 
 
 
 
 
Strain + RNAi
Mean 
survival 
(Days ± 
SEM)
Total 
N
p-value 
vs wt + 
control 
RNAi
p-value vs 
hcf-1(pk924) 
+ control 
RNAi
% of wt 
+ 
control 
RNAi
% effect of 
hcf-1(pk924) 
vs wt + 
RNAi
wt + control 20.94 ± 0.27 324 NA <0.001 NA
wt + daf-16 12.88 ± 0.18 240 <0.001 <0.001 62%
wt + hsf-1 8.45 ± 0.25 220 <0.001 <0.001 40%
wt + smk-1 13.37 ± 0.25 104 <0.001 <0.001 64%
hcf-1(pk924) + control 25.16 ± 0.8 103 <0.001 NA 120% 20%
hcf-1(pk924) + daf-16 12.74 ± 0.3 97 <0.001 <0.001 61% -1%
hcf-1(pk924) + hsf-1 8.22 ± 0.29 123 <0.001 <0.001 39% -3%
hcf-1(pk924) + smk-1 14.57 ± 0.27 83 <0.001 <0.001 70% 9%
Data shown are from one experiment.  Similar results were obtained by Ji Li, Gizem Rizki and Elliot Kahen 
(unpublished).  Statistical analyses were done using SPSS software with Kaplan Meier analysis and log-rank 
test to determine significance.  p-values <0.05 are considered significant. 
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